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1 INTRODUCTION 
1. 1 Breast cancer 
1.1.1 Epidemiology of breast cancer in women  
Breast cancer is one of the most common cancers worldwide. Women living in the 
US have a one in eight chance of being diagnosed with breast cancer. In 2013, an 
estimated 232,340 women were diagnosed with invasive breast cancer, 64,640 
with carcinoma in situ and approximately 39,620 women died (American Cancer 
Society. 2013).  
Breast cancer incidence and mortality increase with age. 79% of new cases and 
88% of breast cancer deaths occurred in women at the age of 50 and older. During 
2006-2010, the average age at diagnosis was 61 (American Cancer Society. 2013).  
A large racial disparity remains in breast cancer. Non-Hispanic white women have 
the highest incidence rates of breast cancer. However, African-American women 
have a higher mortality rate for all age groups (American Cancer Society. 2013). 
1.1.2 Classification of breast cancer 
Greater than 95% of breast cancers are adenocarcinomas, which are divided into 
in situ carcinomas (15-30%) and invasive carcinomas (70-85%). Carcinoma in situ 
is limited to ducts and lobules by the basement membrane, and can be further 
divided into ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS). 
Invasive carcinoma refers to that the cells have the potential to invade into the 
surrounding adjacent normal tissue, reach regional lymph nodes and distant sites. 
No special type includes the majority of invasive carcinoma (79%), followed by 
lobular carcinoma (10%), tubular/cribriform carcinoma (6%), mucinous (colloid) 
carcinoma (2%), medullary carcinoma (2%), papillary carcinoma (1%) and 
metaplastic carcinoma (<1%). 
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Since the distinct biological features correlate with different responses to various 
treatments and affect the long-term prognosis, four subtypes of the most common 
breast cancer type (no special type) have been identified based on the status of 
the estrogen receptor (ER), progesterone receptor (PR) and human epidermal 
growth factor receptor 2 (HER2). Clinically, various statuses of these receptors 
may lead to different prognostic features, which are represented by cell 
proliferation and tumor differentiation. These subtypes include luminal A, luminal B, 
basal-like and HER2 positive (Perou et al. 2000; Perou et al. 2011; Blows et al. 
2010; Habashy et al. 2014; Yersal and Barutca. 2014; Carey et al. 2007; Carey et 
al. 2006). 
Luminal A (50-60%): This is the largest group of breast cancer and is characterized 
by ER+ and / or PR+ / HER2-. The majority occurs in postmenopausal women, 
responds well to hormonal treatments and has good prognosis. 
Luminal B (15-20%): This group is characterized by ER+ and / or PR+ / HER2+. 
This type of breast cancer is aggressive, more likely to have lymph node 
metastases and leads to low survival rates. 
Basal-like (8-37%): This group is also referred to as triple-negative, because of the 
absence of ER, PR and HER2. Basal-like breast cancer is associated with high 
proliferation rate, frequent metastasis, poor prognosis and occurs more often in 
younger premenopausal women.   
HER2-positive (15-20%): This group is distinguished by ER-, PR- and HER2+, 
which is usually poorly differentiated and with poor outcomes. 
1.1.3 Risk factors of breast cancer 
The assessment of breast cancer risk may help to determine whether an 
intervention is appropriate to prevent the development of diseases. Many risk 
factors are non-modifiable, such as age, race/ethnicity, family history, early 
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menarche and late menopause, while the other risk factors are modifiable, 
including obesity, alcohol consumption, smoking and use of combined estrogen 
and progestin menopausal hormones (American Cancer Society. 2013; Mahoney 
et al. 2008, Advani and Moreno-Aspitia. 2014). Several assessment models, such 
as Gail Model, Claus Model, BRCAPRO Model and Cuzick-Tyrer model etc., have 
been developed based on these risk factors and applied for breast cancer 
predication (Amir et al. 2003, Evans and Howell. 2007).  
1.2 Menopausal hormone therapy and breast cancer 
1.2.1 Menopausal hormone therapy induces breast cancer 
Since the early 1940s, when estrogen was first introduced into clinical practice, the 
concern that menopausal hormone therapy (MHT) may cause breast cancer has 
existed. However, millions of women still use it for menopausal symptom relief, 
such as hot flushes and sweats (Rossouw et al. 2002). To understand if indeed 
MHT influence breast cancer, data was collected to provide more reliable evidence. 
Various methods were applied including case reports, case-control studies and 
recently some large prospective cohort studies. Consequently, the concepts about 
MHT and breast cancer have also changed over time. 
In the 1990s, two studies provided important evidences. The Nurses‟ Health Study 
cohort collected information on the menopausal status of 121,700 women ages 30-
55. After 725,550 person-years of follow-up, they found that estrogen alone and 
estrogen plus progestin were both associated with an increased risk of breast 
cancer (Colditz et al. 1995).  The Collaborative Group on Hormonal Factors in 
Breast Cancer reanalyzed 51 studies on the relation between MHT and breast 
cancer risk in 21 countries, and suggested that the relative risk for women who had 
used MHT for 5 years or longer is statistically higher (Collaborative Group on 
Hormonal Factors in Breast Cancer. 1997).  
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In 1993, WHI started two large randomized placebo-controlled clinical trials to 
evaluate the overall health effects of estrogen alone and of estrogen plus progestin. 
In the estrogen plus progestin arms, 16,608 postmenopausal women aged 50-79 
years with an intact uterus were enrolled, and received either 0.625mg/d of 
conjugated equine estrogen (CEE) plus 2.5mg/d of medroxyprogesterone acetate 
(MPA) or placebo. After 5.2 years of follow-up, the risk of breast cancer increased 
by 24% in women receiving estrogen plus progestin compared with placebo. And 
more breast cancers were diagnosed only after the first 4 years in the estrogen 
plus progestin arm compared with placebo (Rossouw et al. 2002) (Figure 1). In the 
estrogen alone arms, 10.739 postmenopausal women aged 50-79 years with prior 
hysterectomy were randomized to either 0.625mg/d of CEE or placebo. No 
increase or even a reduction in breast cancer risk in the estrogen alone arm 
compared to placebo was reported after an average of 7.1 years of follow-up 
(Anderson et al. 2004) (Figure 1). But the possible reduction missed statistical 
significance. In addition, subgroup analyses suggested that estrogen alone may be 
associated with more favorable outcomes in younger women compared with older 
women (Anderson et al. 2004; LaCroix et al. 2011).  
After the publication of the Women`s Health Initiative (WHI) in 2002, the use of 
postmenopausal MHT in the United States dropped over one year from 
approximately 40% to 20% (Hersh et al. 2004), and continued to decline by 52% 
from 2001-2009 (Tsai et al. 2011).  Subsequently, a significant decrease in breast 
cancer incidence was also observed in different countries, such as in the United 
States, Germany, Australia, France and so on (Clarke et al. 2006). And this 
corresponding decrease is not influenced by the changes in frequency of 
mammography (Chlebowski et al. 2009). 
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Figure 1. Women`s Health Initiative (WHI) Hormone Therapy Clinical Trials. 
Invasive breast cancer incidence (Chlebowski et al. 2012). 
Another well-known cohort analysis is the Million Women Study (WMS) in UK, in 
which 1,084,110 women aged 50-64 were enrolled. Incidence of breast cancer was 
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found increased by a factor of 1.30 for current users of estrogen-only therapy, and 
by a factor of 2.00 for current users of estrogen-progestin preparations (Beral et al. 
2003).  
1.2.2 Different preparations of MHT and breast cancer risk 
Based on all the data from observational studies and randomized controlled trials 
that was mentioned above, MHT is now established as carcinogenic to humans 
with respect to breast cancer. And it also shown a higher breast cancer risk 
following estrogen plus progestin therapy compared with estrogen alone. Moreover, 
some experimental and clinical data suggest that different types and regimens of 
MHT may have a different impact on the risk of breast cancer. 
In the WHI hormone therapy trials, 0.625mg/d of CEE with or without 2.5mg/d of 
MPA were used, which represents the vast majority of MHT by far in the US 
(Rossouw et al. 2002). And in the UK, as reported in the MWS, the most commonly 
used estrogens are estradiol (E2) or CEE, and the progestins are mainly 
norethisterone acetate (NET), norgestrel and levonorgestrel (LNG) (Beral et al. 
2003). In Europe, types and regimens of MHT vary in different countries. Instead of 
CEE, E2 is prescribed more frequently in most of European countries. The 
predominant progestins used in Denmark, Germany, Norway, and the Netherlands 
are the testosterone-derived progestins, mainly NET or LNG, whereas the 
progestin preferred in France, Italy and Spain is progesterone derivatives. Overall, 
the most frequently used regimen of combined MHT is progesterone plus NET in 
the sequential treatment mode (Table 1). 
Stahlberg and collages (Stahlberg et al. 2004) analyzed data from the Danish 
Nurse Cohort, including information on MHT types and regimens, reproductive 
history and lifestyle-related factors of 10,874 women aged 45 years and above, 
who used estrogen (mainly E2) alone or estrogen combined with either 
progesterone-like progestins (MPA) or testosterone-like progestins (NET/LNG) in a 
sequential or continuous combined treatment mode. The result showed a 4-fold 
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increased risk of breast cancer with the continuous combined mode. And both 
progesterone-like progestins and testosterone-like progestins were associated with 
a statistically significant higher risk of breast cancer. 
In the French E3N cohort study, data of 80,377 postmenopausal women aged 
between 45-65 years were assessed. Followed for an average of 8.1 
postmenopausal years, 2,354 cases of invasive breast cancer occurred (Fournier 
et al. 2008). Among all the cases, different types of MHT were analyzed. 
Compared with the preparation of estrogen plus progesterone (P4) and estrogen 
plus dydrogesterone (DYD), the combinations of estrogen and other progestins, 
such as MPA, Nomegestrol acetate (NOM) or NET appears to be more harmful 
with regard to breast cancer. However, the association of these progestins with 
breast cancer risk, except for P4 and DYD, did not have significant difference from 
one another. 
In another large prospective cohort, the European Prospective Investigation into 
Cancer and Nutrition (EPIC) cohort study, 133,744 postmenopausal women from 
across Europe were enrolled (Bakken et al. 2011). The data regarding different 
preparations of MHT shows a 43% higher risk of continuous combined regimens 
compared with sequential regimens. And among women who used sequential 
regimens, the associations with breast cancer risk did not differ significantly 
between those who used testosterone-like or progesterone-like progestins. Among 
women who used estrogen-only regimens, risk did not vary significantly between 
those who used E2 or CEE. 
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All 
(n=133,744) 
Denmark 
(n=21,794) 
France 
(n=33,125) 
Germany 
(n=11,575) 
Italy 
(n=14,074) 
Norway 
(n=10,578) 
Spain 
(n=9,360) 
The 
Netherlands 
(n=10,935) 
United 
Kingdom 
(n=22,303) 
Type of estrogens (%) 
Conjugated 
equine 
estrogens 
21.4 1.0 3.5 54.9 8.5 0.0 7.2 27.6 47.5 
Estradiol  61.8 82.3 61.4 37.5 71.0 89.3 50.3 61.2 43.8 
Low-potency 
estrogens 
11.3 4.8 33.5 6.2 20.5 10.2 0.0 8.0 4.7 
Other/unknown 5.5 11.9 1.6 1.4 0.0 0.5 42.4 3.2 3.9 
Type of progestin (%) 
Micronized 
progesterone 
9.5 0.0 24.4 0.1 2.2 0.0 1.1 1.0 0.0 
Progesterone 
derivative 
35.8 19.2 68.6 19.5 83.9 0.7 78.9 30.2 35.3 
Testosterone 
derivative 
53.2 80.8 4.3 80.0 13.9 99.3 0.0 64.6 64.7 
Other/unknown 1.5 0.0 2.7 0.5 0.0 0.0 20.0 4.1 0.0 
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Regimen (%) 
Sequential 44.2 71.6 7.1 69.2 18.2 61.3 2.9 67.4 89.6 
Continuous 
combined 
15.3 24.4 2.2 24.5 0.7 38.1 0.0 5.8 8.5 
Other/unknown 40.5 4.0 90.7 6.3 81.0 0.6 97.1 26.8 1.9 
 
Table 1. Different types and regimens of MHT used among postmenopausal women in the cohort (the EPIC-
study) (Bakken et al. 2011) 
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1.3 PGRMC1 and breast cancer 
1.3.1 Introduction of PGRMC1   
The WHI trial used the combination of CEE plus MPA. In contrast to the WHI 
combined arm, the estrogen only arm shows no increase but rather a reduction 
of breast cancer risk, which was significant for patients with more than 80% 
adherence to study medication. This result indicates a negative effect of 
progestins concerning breast cancer risk. However, the question remains open, 
in as far the combination of estrogens with synthetic progestins as well as with 
natural progesterone may elicit the same increased risk. Thus, there are still 
many questions on the extrapolation of the WHI results to all synthetic 
progestins and to natural progesterone. 
Progestogens are conventionally thought to act via the activation of the 
intracellularly located progesterone receptors (PRs), PR-A and PR-B. Several in 
vitro studies indicate that progestogens can exert an anti-proliferative effect by 
the activation of these receptors in human breast cancer cells (Schoonen et al. 
1995; Cappelletti et al. 1995; Krämer et al. 2006). Nevertheless, still other data 
suggested a proliferative effect of synthetic progestogens (Catherino et al. 
1993; Franke and Vermes. 2003). Thus, the mechanisms by which 
progestogens act on human breast cells remain unclear. Moreover, many 
actions of progesterone are not be able to be explained by the classic genomic 
mechanism of steroid action involving activation of the intracellular transcription 
factors, PR-A and PR-B. On the other hand, evidence has accumulated that 
progesterone can also initiated rapid, cell surface-mediated actions by 
activating membrane receptors and their intracellular signal transduction 
pathways (Revelli et al. 1998; Norman et al. 2004; Thomas. 2012). Recent 
studies revealed that in addition to the intracellular-located receptors, 
progesterone receptor membrane component 1 (PGRMC1) is important to the 
activity of membrane-associated progesterone receptor (Cahill. 2007). 
PGRMC1 was described as a putative progesterone-binding membrane 
receptor (Meyer et al. 1996). Thus, it was named Hpr6.6 (human membrane 
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progesterone receptor) before (Gerdes et al. 1998).  PGRMC1 is a member of a 
multi-protein progesterone-binding complex. Because bacterially expressed 
PGRMC1 does not bind to progesterone (Min et al. 2005), it is now tentatively 
assumed that PGRMC1 does not bind natural progesterone (P4) by itself 
(Cahill. 2007), but requires an unknown protein that is associated only in 
partially purified PGRMC1 preparations (Peluso et al. 2008b). 
1.3.2 PGRMC1 expression and function 
In nonmalignant tissues, PGRMC1 is most highly expressed in the liver and 
kidney (Meyer et al. 1996). However, PGRMC1 is over-expressed in multiple 
types of cancer, including breast, thyroid, colon, ovary, and lung cancer (Rohe 
et al. 2009), and PGRMC1 levels correlate with tumor stage in ovarian cancer 
(Peluso et al. 2008a) and estrogen receptor status in breast cancer (Craven. 
2008; Neubauer et al. 2008).  
In breast cancer tissues, PGRMC1 is strongly expressed in about one-third of 
the investigated tissues. Crudden and colleagues (Crudden et al. 2005) showed 
that PGRMC1 is over-expressed in breast tumors compared with corresponding 
non-malignant tissue. Ji and colleagues (Ji et al. 2012) found that PGRMC1 
does not exist in normal mammary gland, but its expression ranged from strong 
to minimal in breast cancer tissues according to immunohistochemistry. 
Furthermore, expression of PGRMC1 could be detected in 60 samples of breast 
cancer and was significantly correlated to lymph node metastasis, tumor size, 
TNM stage, overall survival rate, and tumor-free survival, but not to each 
patient‟s age or tumor differentiation. In a multivariate survival analysis, 
PGRMC1 was an independent prognostic factor of breast cancer (Ji et al. 2012). 
However, Causey and colleagues (Causey et al. 2011) found, in 28 frozen or 
paraffin-embedded breast cancer samples and ten control benign breast tissue 
samples by RelqPCR, which PGRMC1 mRNA levels decreased significantly 
with patient age. The different results may be due to different detection methods, 
as we know that the expression level of mRNA is not always fully translated into 
protein levels. Another possible reason may be that different ethnic groups have 
been investigated, one from China (Ji et al. 2012), while the other studies were 
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from the USA (Causey et al. 2011). Therefore, in order to harmonize the data, 
more studies among different countries using the same methods are necessary. 
Little is known about how PGRMC1 functions. Since progesterone and the 
synthetic progestins used in MHT are able to activate PR-A/-B and PGRMC1 
simultaneously, which suggests that in vivo the balance of the expression levels 
of both receptors might influence whether epithelial cells proliferate or not in the 
presence of progestogens.  
Our laboratory has previously shown that the synthetic progestins bind to all 
progesterone receptors expressed by breast cancer cell line MCF-7. Binding to 
PR-A/-B in MCF-7 cells might transduce an anti-proliferative signal, 
countermanding the proliferative signal induced by low levels of PGRMC1. In 
contrast, the exogenously expressed PGRMC1, in MCF-7 cells that over 
expressed PGRMC1, might overrule the anti-proliferative effect of PR-A/-B. 
Therefore, it may be instructive to determine the expression ratio of PGRMC1 
and PR-A/-B before MHT. 
1.3.3 PGRMC1 in regulating breast cancer cell proliferation in vitro 
Our laboratory compared the effect of the main synthetic progestins, which are 
used for MHT or natural progesterone alone, as well as combined with 
estrogens, on MCF-7 cells and PGRMC1 over-expressed MCF-7 cells (WT-12). 
As such, these cell lines mimic the PGRMC1 expression profile of breast 
cancer. 
Interestingly, among all these natural progesterone (P4) and different synthetic 
progestins, including chlormadinone acetate (CMA), desogestrel (DSG), 
dienogest (DNG), drospirenone (DRSP), dydrogesterone (DYD), levonorgestrel 
(LNG), medroxy-progesterone acetate (MPA), nomegestrol (NOM) and 
norethisterone (NET), NET is most effective for the prolieration of all the cell 
lines, followed by DNG, DRSP, DSG, DYD, LNG, while no effect was found for 
CMA, NOM and P4. The proliferation effect on WT-12 cells is more significant 
than MCF-7 cells. These results demonstrated that progestogens act variant on 
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breast epithelial cells and different in their ability to induce proliferation. NET 
binds PGRMC1 with the highest affinity, which indicates MHT including NET 
might result in an increased risk for breast cancer development (Neubauer et al. 
2009; Seeger et al. 2003).  
Estrogen plus progestogens results showed estradiol (E2) can elicit a significant 
proliferation of WT-12 cells at 10-10 M. However, E2 alone at 10-12 M showed no 
significant effect. Addition of progesterone or the synthetic progestogens (MPA, 
NOM) in a sequentially or continuously combined manner did not significantly 
alter the estradiol-induced proliferation. However, NET showed a significant 
increased proliferation rate when combined with estradiol in a concentration of 
10-12 M, and the increase being higher for the continuous combination. The E2- 
and NET-induced proliferation could be abrogated by the addition of an 
estrogen receptor antagonist. Women with breast cancer cells that over-express 
PGRMC1 may be more susceptible in developing breast cancer and thus may 
have a much higher breast cancer risk when treated with estrogen therapy 
alone and especially when treated with estrogen combined with certain 
synthetic progestins than those not expressing PGRMC1 (Ruan et al. 2012; 
Neubauer et al. 2013). 
1.3.4 ER status and potential PGRMC1 functional model 
Estrogen receptor (ER) status is a critical biomarker in breast cancer, not only 
because it is an indicator of prognosis of breast cancer, but also because ER is 
the target of tamoxifen and similar drugs. In our previous studies, Neubauer and 
colleagues suggested that PGRMC1 correlates with ER status (Neubauer et al. 
2008). ER-negative tumors have elevated levels of PGRMC1, whereas 
PGRMC1 was phosphorylated in ER-positive tumors. 
There are limited data concerning PGRMC1-activated signaling pathways. 
PGRMC1 has a role in regulating protein kinase-associated signaling in which 
PGRMC1 increases Akt activation and IkB phosphorylation leading to NFkB 
activation (Hand and Craven. 2003). PGRMC1 is a protein of 194 amino acids 
(21.5 kDa) with target sequences for two Src homology 2 (SH2), a Src 
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homology 3 (SH3) (Cahill. 2007), a tyrosine kinase site, and two acidophilic 
kinase sites, such as casein kinase 2 (CK2) (Table 2). This protein functions as 
a signaling adaptor molecule involved in membrane trafficking, and that the 
activity may be kinase- and/or ligand-regulated.  
Unlike the traditional PRs, PGRMC1 does not bind directly to progesterone (Min 
et al. 2005), but rather binds to binding partners, such as P450. PGRMC1 
shares key structural motifs with cytochrome b5 (Mifsud and Bateman. 2002), a 
heme binding protein that activates cytochrome P450 proteins (Schenkman and 
Jansson. 2003). In ER-negative tumors, PGRMC1 binds and activates P450 
proteins (Min et al. 2005), which metabolize drugs, hormones and lipids and 
produces a metabolite or by-product that triggers Akt phosphorylation. P450-
mediated oxidative damage is a candidate mechanism for tumor formation (Min 
et al. 2005). And PGRMC1 promotes cell death in cancer cells after oxidative 
damage (Hand and Craven. 2003), possibly due to its activation of P450 
proteins, activates the pro-survival protein kinase Akt. Akt is phosphorylated by 
the PDK1 protein kinase, and there is a putative PDK1 binding region on 
PGRMC1 (Cahill. 2007). On the other hand, PGRMC1 may also be able to bind 
directly to an Akt activator (Cahill. 2007). Because PGRMC1 has several 
potential binding sites for interacting proteins, it might act as a type of adaptor 
protein, providing docking sites for proteins that activate Akt, such as PDK1. 
Sites like S56 and S180 are required to activate Akt after oxidative damage in a 
PGRMC1-overexpressing cell line. 
PGRMC1 contains several sites for phosphorylation and is phosphorylated in 
ER-positive tumors, suggesting that there is an ER-regulated kinase that 
phosphorylates PGRMC1. In the CK2-phosphorylated state, one or more of the 
N-terminal SH3 target motif and C-terminal SH2 target motif may be 
phosphorylated by an acidophilic kinase such as CK2, and do not interact with 
other proteins. However, the relevant kinase and the possible mechanism of ER 
regulating PGRMC1 to influence breast cancer progress remain unclear. 
1.4 Aims of the following work 
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Aim of the first part of the present work is to determine the influence of 
modification of different PGRMC1 phosphorylation sites together with various 
preparations of estrogens and progestogens on the proliferation of breast 
cancer cell lines. Moreover, the main focus of the second part is on identifying 
the potential ER-regulated kinase that participates in the phosphorylation of 
PGRMC1. Furthermore, the transcription level of an ER reporter gene is 
evaluated, to prove the involvement of a cross-talk between PGRMC1 and ER 
in estrogen/progestogen-regulated breast cancers. 
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Table 2. Protein motifs predicted for PGRMC1 (SwissProt entry O00264) using the Scansite cell signaling 
interactions prediction “MotifScan” module (http://scansite.mit.edu/motifscan id.phtml) under medium stringency. (Cahill. 
2007) 
Position Motif predicted Consensus type Sequence 
S56a Acidophilic S/T Kinase CK2-P QPAASGDSDDDEPPP 
P62a SH3 target sequence Crk/Grb2/Abl/Src DSDDDEPPPLPRLKR 
P108 Kinase binding ERK1 binding KGRKFYGPEGPYGVF 
Y112 Tyr-Kinase Lck/Abl-p FYGPEGPYGVFAGRD 
Y138 SH2 target sequence Shc KEALKDEYDDLSDLT 
T160 Kinase binding PDK1 binding SDWESQFTFKYHHVG 
Y179a SH2 target sequence Fgr/SHIP EGEEPTVYSDEEEPK 
S180 Acidophilic S/T Kinase CK2-P GEEPTVYSDEEEPKD 
Bold underlined amino acids represent those indicated in the ‟Position‟ column, at the centre of each predicted motif. 
aMotifs that were also predicted under high stringency “MotifScan” settings. 
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2. MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Reagents 
Table 3: Estrogens and Progestins 
Name Abbreviations Company 
Estrone E1 Sigma (Munich, Germany) 
Estradiol E2 Sigma (Munich, Germany) 
Estriol E3 Sigma (Munich, Germany) 
Estetrol E4 Sigma (Munich, Germany) 
Ethinyl estradiol EE Schering (Berlin, Germany) 
Equilin Eq Steraloids (Newport, Island) 
17α-Dihydroequilin DHEq Steraloids (Newport, Island) 
Progesterone P4 Sigma (Munich, Germany) 
Norethisterone acetate NET Sigma (Munich, Germany) 
Medroxyprogesterone 
acetate 
MPA Sigma (Munich, Germany) 
Levonorgestrel LNG Sigma (Munich, Germany) 
Chlormadinone acetate CMA Sigma (Munich, Germany) 
Desogestrel DSG Sigma (Munich, Germany) 
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Dienogest DNG Schering (Berlin, Germany) 
Drospirenone DRSP Schering (Berlin, Germany) 
Dydrogesterone DYD 
LGM Pharma (Boca Raton, 
USA) 
Nomegestrolacetate NOM 
LGM Pharma (Boca Raton, 
USA) 
Cyproterone acetate CYA Schering (Berlin, Germany) 
 
The compounds were dissolved in ethanol to give a concentration of 10-2 M and 
were stored as concentrated stock solutions at -20C.  
Table 4: Inhibitors 
Name Function Company 
TBCA Casein Kinase II Inhibitor III 
Calbiochem (Darmstadt, 
Germany) 
Fulvestrant Estrogen receptor antagonist Sigma (Munich, Germany) 
Tamoxifen 
Selective estrogen receptor 
modulator 
Sigma (Munich, Germany) 
AG205 PGRMC1 inhibitor Timtec, Inc. (Newark, USA) 
 
The compounds were dissolved in DMSO to give a concentration of 10-2 M and 
were stored as concentrated stock solutions at -20C.  
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The growth factors Epidermal Growth Factor (EGF), Fibroblast Growth Factor-
Basic (bFGF) and Insulin-like Growth Factor (IGF-I) were purchased from Sigma 
Chemicals. The compounds were reconstituted according to the manufacturer‟s 
instructions stated on the package insert and were stored in aliquots at -20C. 
2.1.2 Cells and cell culture 
MCF-7 
MCF-7, an ER+ and PR+ invasive breast ductal carcinoma cell line isolated in 
1970 from a 69-year-old Caucasian woman, was purchased from American Type 
Culture Collection (ATCC). MCF-7 cells stably transfected with PGRMC1 and 
mutants, respectively, were established. Expression plasmid pcDNA3.1 containing 
hemagglutinin (HA)-tagged mPR (PGRMC1) wild-type or HA-tagged mutants S56A, 
S180A, S56A/S180A, were transfected into MCF-7 breast cancer cells (Table5). 
Stable transfection was verified by PCR using chromosomal DNA and primers 
spanning intron 1 to distinguish integrated PGRMC1 cDNA from the chromosomal 
sequence. The sequences of the primers were 5‟-CTGCTGCATGAGATTTTCACG-
3‟ hybridizing to nucleotides 71–91 of PGRMC1 open reading frame and 5‟- 
GCATAGTCCGGGACGTCATA-3‟ hybridizing to the sequence coding for the HA 
tag. PCR products were sequenced. 
Untransfected cells were routinely cultured in RPMI-1640 medium containing 10% 
(v/v) heat inactivated fetal calf serum (FCS), 25mM HEPES and 1% 
penicillin/streptomycin at 37°C in a humid 5% CO2 atmosphere. Transfected cells 
were also maintained in the same condition but with an additional 100 μg/mL 
hygromycin B, purchased from Invitrogen, Karlsruhe, Germany. Cells were fed 
every three to four days. Cultures were split weekly at a ratio of 1:3 to 1:4 after 
treatment with trypsin (0.04%)-EDTA (0.03%) for 5 minutes followed by trypsin 
neutralisation with medium, both purchased from Gibco, and centrifugation at 
1200rpm for 5 minutes. The cell pellet was resuspended in the appropriate growth 
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medium for subculture or assay work. 
Table 5: MCF-7 and mutant cell lines 
Name Mutant Sequence 
MCF-7 Untransfected  
Mut A S56A serine-56 to alanine: AGC → GCC 
Mut B S180A serine-180 to alanine: TCA → GCA 
Mut C S56A/S180A 
serine-56 to alanine: AGC → GCC 
serine-180 to alanine: TCA → GCA 
WT-12 PGRMC1 wild-type   
EVC Empty vector control  
 
T47D 
T47D, a human ER+ primary breast cancer cell line, was purchased from American 
Type Culture Collection (ATCC). T47d cells were stably transfected with 
expression vector pc-DNA3.1 containing hemagglutinin-tagged (3HA) PGRMC1 as 
described below. 
Untransfected cells were routinely cultured in RPMI-1640 medium containing 10% 
(v/v) heat inactivated fetal calf serum (FCS), 25mM HEPES, 1mM sodium pyruvate, 
and 1% penicillin /streptomycin at 37°C in a humid 5% CO2 atmosphere. 
Transfected cells were also maintained in the same condition but with additional 
40μg/mL hygromycin B, purchased from Invitrogen, Karlsruhe, Germany. Cells 
were fed every three to four days. Cultures were split weekly at a ratio of 1:3 to 1:4 
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after treatment with trypsin (0.04%)-EDTA (0.03%) for 5 minutes followed by 
trypsin neutralization with medium, both purchased from Gibco, and centrifugation 
at 1200rpm for 5 minutes. The cell pellet was resuspended in the appropriate 
growth medium for subculture or assay work. 
Table 6: T47D and mutant cell lines 
Name Mutant 
T47D Untransfected 
WT-3 Wild-type 
EVC Empty vector control 
 
2.2 Methods 
2.2.1 Transfection of T47D cells 
T47D cells were stably transfected with expression vector pc-DNA3.1 containing 
hemagglutinin-tagged (3HA) PGRMC1 using lipofectamineTM 2000 (Invitrogen, 
Karlsruhe, Germany), in accordance with the manufacturer‟s recommendation. A 
total of 5×105 cells were transfected and plated with RPMI medium for 24h. Then, 
the medium was changed to RPMI complete medium containing hygromycin B. 
Cells were cultured for 2 weeks for selection of stable integration events. 
Transfection rates were measured by cotransfection of a GFP-expressing plasmid 
and immune fluorescence analysis. After 2 weeks single colonies had formed and 
limiting dilutions were performed three times to select for colonies grown from a 
single cell. 
Stable transfection was verified by PCR using chromosomal DNA and primers 
spanning intron 1 to distinguish integrated PGRMC1 cDNA from the chromosomal 
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sequence. The sequences of the primers were 5‟-CTGCTGCATGAGATTTTCACG-
3‟ hybridizing to nucleotides 71–91 of PGRMC1 open reading frame and 5‟-
GCATAGTCCGGGACGTCATA-3‟ hybridizing to the sequence coding for the HA 
tag. PCR products were sequenced. And the efficiency of the transfection was 
determined using the Immune fluorescence analysis as described below. 
2.2.2 Immune fluorescence analysis 
The immune cytochemical fluorescence analysis of cytospins was performed using 
a humidified chamber. For preparation of cytospins, 5×104 cells were resuspended 
in 500mL PBS spun onto slides using Cytospin 2 centrifuge (Shandon, Waltham, 
MA, USA) at 1000 rpm for 5 min. Then, the cytospins were dried overnight at room 
temperature and stored at -20°C until further use. 
Table 7: Antibodies used for Immune fluorescence analysis 
 Name Dilution Company 
Primary 
antibody 
Anti-Cytokeratin Pan FITC 
conjugated (C11) 
1:400 Santa Cruz, CA, USA 
Primary 
antibody 
Rabbit anti-HA (Y11) 1:100 Santa Cruz, CA, USA 
Secondary 
antibody 
Goat anti-mouse AlexFluor 
594 
1:100 
Invitrogen, Karlsruhe, 
Germany 
 
Cytospins were investigated by fixing the cells in 50ml 0.05% formalin in PBS for 
90s at room temperature, followed by a wash step for 3min in PBS. Then the slides 
were placed on ice and permeabilized using 50ml 0.1% Triton X-100 in PBS for 
15min. Afterwards, the cytospins were washed three times for 3min with PBS. 
Blocking of unspecific antibody binding sites was performed with serum of the 
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species, which was the source of the secondary antibody – goat in our case. To 
that aim, goat serum was diluted 1: 10 in Antibody Diluent (Dako Cytomation, 
Glostrup, Denmark) and 50ml of this diluted serum was pipetted onto the slides 
and incubated for 30min at room temperature. Then the block was removed and 
incubated with the first antibody for 60min at room temperature, followed by 
washing the cytospins in PBS for 3min. Secondary antibodies were incubated for 
30min at room temperature. Finally, the cytospins were washed twice for 3min with 
PBS and mounted with Vectashield Mounting Medium with DAPI (Vector 
Laboratories, Burlingame, USA). 
2.2.3 MTT assays 
Proliferation of treated cells was also determined by measuring the enzymatic 
cleavage of the tetrazolium ring of the yellow tetrazolium salt 3- (4,5-
dimethylthiazol-2-yl) 2,5-diphenyl-tetrazolium bromide (MTT) by mitochondrial 
dehydrogenase, resulting in a blue, water-insoluble formazane salt. The MTT salt 
was dissolved in RPMI 1640 medium without phenol red to a concentration of 
1mg/ml filtered sterile and further diluted 1: 4 with RPMI 1640 medium without 
phenol red. 
Cells were trypsinized and counted using a Neubauer Cell Counter 
(Hemocytometer). 90L of the marker „tryphan blue‟ and 10L of cell suspension 
were mixed thoroughly in a well in a 96-well plate, kept specifically for this purpose. 
10L of the marker/cell suspension mixture was placed on either side of a 0.1mm-
deep chamber in the Hemocytometer and observed under a microscope. The 
number of cells in a defined area was counted and the cell concentration derived 
from the count.  
Cells were seeded with 5000 cells per well in a 96-well plate. After 24h of 
incubation, the culture medium was changed to medium with stripped FCS. 
Estrogens alone or in combination with different progestins in a continuous 
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combined of sequential regimen were then added in to the medium. After 6 days of 
stimulation, medium was decanted from the 96-well plate used to incubate the cells. 
Then 100ml MTT solution was added to each well and incubated for 3h at 37°C. 
Crystallized formazane salt was centrifuged for 10 min with 400g and supernatant 
was discarded. The resulting salt was solubilized in 0.1ml sterile DMSO added into 
each well and the plate was shaken for 7min at room temperature. Analysis was 
performed using an ELISA-reader at a wavelength of 550nm. The resulting 
extinction is proportional to the amount of cells present in the well. (Diary plans in 
table 8, 9, and 10). 
Table 8: Normal stimulation 
Day 0 Cell seeding 
Day 1 Change to medium with stripped FCS 
Day 3 Change to estrogens or progestins in Medium with stripped FCS 
Day 5 Change to estrogens or progestins in Medium with stripped FCS 
Day 7 Change to estrogens or progestins in Medium with stripped FCS 
Day 9 MTT assay 
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Table 9: Continuous combined stimulation 
Day 0 Cell seeding 
Day 1 Change to medium with stripped FCS 
Day 3 Change to estrogens plus progestins in Medium with stripped FCS 
Day 6 Change to estrogens plus progestins in Medium with stripped FCS 
Day 9 MTT assay 
 
Table 10: Sequential stimulation 
Day 0 Cell seeding 
Day 1 Change to medium with stripped FCS 
Day 3 Change to estrogens in Medium with stripped FCS 
Day 6 Change to estrogens plus progestins in Medium with stripped FCS 
Day 9 MTT assay 
 
2.2.4 Western blot analysis 
Cells were washed twice with ice-cold phosphate buffered saline (PBS) and lysed 
in M-PER mammalian protein extraction reagent containing Halt Protease Inhibitor 
Cocktail according to the manufacturer‟s protocol (both from Pierce, Rockford, IL, 
USA). Protein concentrations were determined using the BCA Protein Assay Kit 
(Pierce). In total, 25µg of protein extract was loaded per lane onto a 10% 
polyacrylamide gel and separated by electrophoresis. The gel was blotted onto a 
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Hybond ECL nitrocellulose membrane (Amersham, Piscataway, NJ, USA) at 15V 
for 90min using a semi-dry blot system. The membrane was blocked for 2h at room 
temperature using 5% dried low fat milk powder dissolved in TBST buffer (50mM 
Tris-HCl, pH 7.4, 150mM NaCl, 0.1% Tween 20). Then, the first antibody was 
incubated overnight at 48°C. After washing three times with TBST, the second 
antibody was incubated for 2.5h at room temperature. Chemiluminescence was 
generated using the ECL Western Blotting Analysis System (Amersham). The 
signals were measured and quantified with Lumi-Imager and LumiAnalyst 3.1 
software (Boehringer, Mannheim, Germany).  
Table 11: Antibodies used for western blot analysis 
 Name Dilution Company 
Primary 
antibody 
Phospho-PGRMC1-specific mouse 
monoclonal antibody 3G11A2 
1:200  
Primary 
antibody 
Anti-Actin antibody produced in 
rabbit 
1:1000 
Santa Cruz, 
CA, USA 
Secondary 
antibody 
Goat anti-mouse IgG-HRP 1:1000 
Santa Cruz, 
CA, USA 
Secondary 
antibody 
Goat anti-rabbit IgG-HRP  1:1000 
Santa Cruz, 
CA, USA 
 
2.2.5 Extraction of RNA and cDNA synthesis 
Expression of TFF1 was determined with real-time polymerase chain reaction (RT-
PCR). Messenger RNA was extracted using the RNeasy Mini Kit (Qiagen, Hilden, 
Germany) according to the manufacturer‟s instructions and stored at -20°C until 
cDNA synthesis using a standard protocol. Briefly, 1μg total RNA was incubated for 
42 
 
30min with 2μl DNase I (Amplification Grade DNase I Kit; Sigma, St. Louis, MO, 
USA) at room temperature. After thermal inactivation of DNase I at 70°C for 10min, 
cDNA synthesis was done using random and oligo(dT) primers and Superscript II 
RNase H reverse transcriptase (Invitrogen). Reverse transcriptase reaction was 
performed at 42°C for 50 min and 72°C for 15min.To check cDNA quality control, 
RT-PCR was performed for the pyruvate dehydrogenase β- subunit (PDH) to verify 
absence of genomic DNA. 
2.2.6 Quantitative real-time PCR 
Quantitative RT-PCR (qRT-PCR) was performed with the LightCycler System 
(Roche) and SYBR Green incorporation according to the manufacturer‟s 
instructions. At the end of the PCR, the reaction melting curve was determined to 
check for the purity of the PCR reaction. 
For efficiency-corrected relative quantification of gene expression, triplicate 
reactions were set up. Expression of PDH was used to normalize the relative 
regulation of candidate genes employing the efficiency corrected equation. 
Efficiency of every single PCR reaction was determined by using Rest-384 
software. 
Table 12: Primers used for qRT-PCR 
Name Company 
Hs_TFF1_1_SG Qiagen, (Hilden, Germany) 
PDH classic Invitrogen (Karlsruhe, Germany) 
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2.3 Statistics 
All proliferation experiments were done in triplicates and were repeated at least 
three times, with each experiment yielding essentially identical results. Statistical 
analysis was done by ANOVA with the logarithmated values followed by Dunnett‟s 
procedure from triplicates of at least three independent experiments. The overall 
alpha level was set at 0.05. 
Most of the qRT-PCR experiments were done in triplicate once, due to the lack of 
time, while some of them were repeated twice. From these values, means were 
calculated alone with standard deviation (S.D.). Statistical analysis was performed 
using Rest-384 software. 
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3. RESULTS 
3.1 Transfection of T47D cells with PGRMC1 coding expression plasmids 
Transfection rates measured by cotransfection of a GFP expressing plasmid were 
around 40-50%. After limiting dilution PGRMC1-3HA transfected T47D cells were 
prepared for cytospins and immune fluorescence analysis was performed using 
anti-HA antibody indicating that the transfected cell line was almost devoid of 
untransfected MCF-7 cells (Fig. 2). 
Western Blot analysis for the PGRMC1-3HA fusion protein resulted in a single 
band at approximately 30 kDa, which is the predicted size of 28kDa for PGRMC1 
plus approx. 3kDa for the three HA tags. The untransfected T47D produced only a 
very faint signal at 28 kDa indicating a weak intrinsic PGRMC1 expression. Similar 
signal intensities for the housekeeping protein actin (approx. 42kDa) indicate 
loading of equal amounts of total protein.  
 
Figure 2. Over-expression of PGRMC1 in T47D cells. Immunofluorescence 
analysis of cytospin preparations from T47D (left) and T47D/PGRMC1-3HA 
(right) cells. PGRMC1-3HA is detected with anti-HA antibody conjugated with 
Alexa 594. Cell nuclei are stained with DAPI. Magnification: 40×. 
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PCR products from chromosomal DNA of the transfected cell lines provided the 
expected signal in the agarose gel. Sequencing of PCR products confirmed the 
PGRMC1 wild type sequence. At the end of the experiments the high purity of the 
T47D/PGRMC1-3HA cells was validated by immune fluorescence analysis of 
cytospins and by sequencing PCR products. These results indicated that T47D/ 
PGRMC1-3HA cells are highly pure, overexpress PGRMC1 wild type protein and 
can be used for functional assays.  
MTT assay was performed to in investigated potential differences in the basal 
proliferation of T47D and T47D/PGRMC1-3HA (WT-3) cells. The latter showed a 
significant higher proliferation after day 6. 
3.2 MTT assay 
3.2.1 Proliferative effect of progestogens or estrogens alone on MCF-7 and 
T47D cells 
First, a fixed concentration of progesterone (P4) or different synthetic progestins 
(10
-6
M, 10
-7
M) was incubated with both cell lines. The proliferation rate was 
measured after 6 days (Fig. 3, 4).  
All MCF-7 cell lines except MutC were able to significantly respond to different 
progestins (Fig. 3). P4 and NOM triggered only the proliferation of MutA and EVC, 
but in a relatively low level. In comparison to all other synthetic progestins tested, 
NET had the strongest proliferative effect especially on MutB. MutC did not 
respond to any progestins. And the proliferation effect of EVC was also weaker 
than MutA, MutB and WT-12. 
P4 and all progestins were able to significantly stimulate the proliferation of T47D 
EVC and untransfected T47D cells (Fig. 4). WT-3 did not respond to P4 and NOM 
at the concentrations of either 10
-6
M or 10
-7
M. Also, at the concentration of 10-7M, 
MPA, LNG, CYP did not have any effect on WT-3 cells. EVC and T47D had similar 
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reactions on different progestins, while the proliferative rate of WT-3 was obviously 
higher than the other T47D cell lines. 
 
Figure 3. MCF-7 MutA, MutB, MutC, WT-12, and EVC cells were incubated 
with MPA, P4, DNG, NOM, LNG, and NET each at concentration of 10-6M. Cell 
proliferation was measured after 6 days. Data were normalized to ethanol (10-
3M) stimulated control cells. (Means±SD; *p < 0.05; **p < 0.01 vs. controls). 
With regard to the proliferative effect triggered by different estrogens, MCF-7 and 
T47D cell lines were incubated with E1, E2, E3, E4, Eq, DHEq, and EE at 
concentrations of 10
-12
M, 10
-11
M and 10
-10
M, respectively. The proliferation rate 
was measured after 6 days (Fig. 5, 6). 
Dose-dependent effects on cell proliferation of estrogens except DHEq were 
observed (Fig. 5): for all the estrogens except DHEq at concentrations from of 10
-
12
M to 10
-10
M with a maximal effect at 10
-10
M. Almost no effects were observed in 
EVC and untransfected MCF-7 cells within the investigated concentration ranges 
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for all the estrogens used in this experiment. EE showed the strongest effect 
compared to all the other estrogens at all three concentrations. 
The similar dose-dependent proliferative effects of estrogens on T47D cells were 
also detected (Fig. 6). However, unlike MCF-7 cells, T47D EVC and untransfected 
T47D cells were able to react to different estrogens. All the estrogens except DHEq 
increased the proliferation of T47D cells significantly, and would reach their 
maximal effect at 10
-10
M, the highest concentration that we tested.  
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Figure 4. T47D WT-3, EVC, and untransfected T47D cells were incubated with P4, MPA, DNG, NOM, LNG, 
DSG, CMA, CYP and NET each at concentrations of 10-7M and 10-6M. Cell proliferation was measured after 6 
days. Data were normalized to ethanol (10-3M) stimulated control cells. (Means±SD; *p < 0.05; **p < 0.01 vs. 
controls).
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Figure 5. MCF-7 WT-12, EVC and untransfected MCF-7 cells were incubated with E1, E2, E3, E4, Eq, DHEq 
and EE each at concentration of 10-12M, 10-11M and 10-10M. Cell proliferation was measured after 6 days. Data 
were normalized to ethanol (10-3M) stimulated control cells. (Means±SD; *p < 0.05; **p < 0.01 vs. controls). 
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Figure 6. T47D WT-3, EVC, and untransfected T47D cells were incubated with E1, E2, E3, E4, Eq, DHEq and 
EE each at concentrations of 10-12M, 10-11M and 10-10M. Cell proliferation was measured after 6 days. Data 
were normalized to ethanol (10-3M) stimulated control cells. (Means±SD; *p < 0.05; **p < 0.01 vs. controls).
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3.2.2 Proliferative effect of estrogens in combination with progestins on 
MCF-7 and T47D cells 
To investigate the proliferative effect of MCF-7 and T47D cells after stimulation of 
estrogens in combination with progestins. Cells were incubated with estrogens 
alone as well as estrogens in addition with progestins in either a continuous 
combined or a sequential manner. By continuous combined manner, it means that 
cells were incubated 6 days with the combination of estrogens and progestins. And 
by sequential manner, cells were stimulated 3 days by estrogens alone, and by the 
combination of estrogens and progestins for the next 3 days. The proliferation rate 
was measured after 6 days (Fig. 7-12). 
For MCF-7 cells and mutants, as can be seen in Figure 7, 8, NET alone at the 
concentration of 10
-7
M elicited significant proliferation of MutA, MutB and WT-12, 
which is consistent with the results mentioned above. E2 alone at the 
concentrations of 10
-12
M and 10
-10
M elicited also a significant proliferative increase 
of MutA, MutB and WT-12 cells. And the effect was clearly dose-dependent. 
However, the increased proliferation of EVC was triggered only by E2 alone at a 
lower concentration range, 10
-14
M and 10
-12
M. Addition of NET (10
-7
M) to E2 in 
both continuous combined and sequential manner altered the E2-induced 
proliferation significantly: for MutA at the E2 concentration of 10
-14
M and 10
-12
M 
continuously and at the concentration of 10
-14
 M sequentially, for MutB at the E2 
concentration of 10
-14
M continuously, and for WT-12 at the E2 concentration of 10
-
14
M and 10
-12
M continuously and at the concentration of 10
-14
 M sequentially. 
In a further experiment with MCF-7 WT-12 cells EE and E2 (10
-10
M and 10
-9
M) was 
continuously or sequentially added with CMA, CYP, DSP, LNG, and NET at the 
concentration of 10
-6
M. As can be seen in Figure 9, 10, CMA and CYP alone had 
no significant effect on WT-12 cells, while DSP and NET had obviously strong 
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effect. EE and E2 in both concentrations elicited significant proliferation of WT-12, 
but the addition of some progestins increased these proliferative effects compared 
with estrogens alone: for CMA added in EE at the concentration of 10
-9
M 
continuously, for CYP added in EE at the concentration of 10
-9
M continuously and 
sequentially, for DSP added in EE at the concentration of 10
-9
M continuously and 
at EE10
-10
M, 10
-9
M and E2 10
-10
M sequentially, and for NET in all the combination 
that we tested. 
For T47D cells, the proliferative effects of estrogen and progestins were also 
investigated. As shown in Figure 11, 12, the effects of 10
-6
M NOM, 10
-7
M DSP, 10
-
7
M and 10
-6
M DSG, 10
-7
M and 10
-6
M NET, 10
-7
M and 10
-6
M CMA, and 10
-7
M CYP 
on T47D WT-3 cells in the presence of E2 at the concentration of 10
-10
M in the 
continuous combined manner significantly increased. Moreover, the proliferation of 
EVC was also significantly enhanced by the continuous combined E2 and NOM 
(10
-7
M and 10
-6
M), as well as by E2 and NET (10
-7
M and 10
-6
M). However, no 
significant difference of the effect of estrogen and progestin combination compared 
with estrogen alone could be found for T47D WT-3 and EVC cells in the sequential 
manner.
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Figure 7. MCF-7 MutA, MutB, MutC, WT-12, and EVC cells were incubated with E2 (10-14M, 10-12M and 10-10M) 
alone and in combination with NET (10-7M) continuously. Cell proliferation was measured after 6 days. Data 
were normalized to ethanol (10-3M) stimulated control cells. (Means±SD; *p < 0.05; **p < 0.01 vs. E2 alone). 
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Figure 8. MCF-7 MutA, MutB, MutC, WT-12, and EVC cells were incubated with E2 (10-14M, 10-12M and 10-10M) 
alone and in combination with NET (10-7M) sequentially. Cell proliferation was measured after 6 days. Data 
were normalized to ethanol (10-3M) stimulated control cells. (Means±SD; *p < 0.05; **p < 0.01 vs. E2 alone). 
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Figure 9. MCF-7 WT-12 cells were incubated with EE and E2 (10-10M and 10-9M) alone and in combination with 
various progestins (10-6M) continuously. Cell proliferation was measured after 6 days. Data were normalized 
to ethanol (10-3M) stimulated control cells. (Means±SD; *p < 0.05; **p < 0.01 vs. E2 alone). 
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Figure 10. MCF-7 WT-12 cells were incubated with EE and E2 (10-10M and 10-9M) alone and in combination 
with various progestins (10-6M) sequentially. Cell proliferation was measured after 6 days. Data were 
normalized to ethanol (10-3M) stimulated control cells. (Means±SD; *p < 0.05; **p < 0.01 vs. E2 alone). 
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Figure 11. T47D WT-3 and EVC cells were incubated with E2 (10-10M) alone and in combination with various 
progestins (10-7M and 10-6M) continuously. Cell proliferation was measured after 6 days. Data were 
normalized to ethanol (10-3M) stimulated control cells. (Means±SD; *p < 0.05; **p < 0.01 vs. E2 alone). 
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Figure 12. T47D WT-3 and EVC cells were incubated with E2 (10-10M) alone and in combination with various 
progestins (10-7M and 10-6M) sequentially. Cell proliferation was measured after 6 days. Data were 
normalized to ethanol (10-3M) stimulated control cells. (Means±SD; *p < 0.05; **p < 0.01 vs. E2 alone). 
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3.2.3 Blocking effect of TBCA on the prolieferation of MCF-7 cells 
First, NET or TBCA was used alone and in combination continuously or 
sequentially on MCF-7 WT-12 cells to determine the best manner. By continuous 
combined manner, it means that cells were incubated 6 days with NET and TBCA 
combination. And by sequential manner, cells were treated 3 days by TBCA alone, 
and by NET and TBCA combination for the next 3 days. The proliferation rate was 
measured after 6 days (Fig. 13).  
 
Figure 13. MCF-7 WT-12 cells were incubated with NET (10-6M) and TBCA (10-
6M, 10-7M, 10-8M and 10-9M) alone respectively, and in combination 
continuously or sequentially. Cell proliferation was measured after 6 days. 
Data were normalized to ethanol (10-3M) stimulated control cells. (Means±SD; 
*p < 0.05; **p < 0.01 vs. NET alone). 
TBCA alone showed no effect on the proliferation of WT-12 cells. And NET alone 
showed strong effect of increased cell proliferation. In the sequential manner, the 
proliferative effect of NET was significantly reduced compared with NET alone. 
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However, the reduction seemed not dose-dependent. The similar blocking effect 
was not observed in the continuous combined manner. Therefore, the sequential 
manner was chosen for further kinetic experiments. 
To determine the best blocking concentration of TBCA, titration experiments were 
then performed. TBCA alone showed no effect on the proliferation of all MCF-7 
cells. And NET and E2 alone showed consistently intensify of cell proliferation. As 
can be seen in Figure 14,15, the NET-induced effect could be reversed by the 
addition of TBCA: for Mut A at the concentration of TBCA 10
-6
M and 10
-4
M, for 
MutB at the concentration of TBCA 10
-7
M, 10
-6
M, 10
-5
M and 10
-4
M, for WT-12 at 
the concentration of TBCA 10
-7
M, 10
-6
M and 10
-5
M, and for EVC at the 
concentration of TBCA 10
-4
M. Also, the E2-induced effect could be reversed. 
Especially, the proliferation of WT-12 caused by E2 was significantly blocked by 
TBCA at all the concentrations that we tested. However, these blocking effects did 
not seem to be dose-dependent. Moreover, MutC still not reacted to any 
stimulation. For further experiments, 10
-6
M was chosen. 
Three parallel experiments were then performed to investigate the ability of TBCA 
on blocking the effect of NET and E2 at various concentrations. MCF-7 MutA, MutB, 
MutC, WT-12, and EVC cells were stimulated by NET, E2 and GF (EGF, FGF and 
IGF-I) at different concentrations. As shown in Figure 16, NET alone elicited the 
proliferation of MutA, MutB, WT-12, and EVC cells significantly, while TBCA alone 
had no effect, which is consistent with the results mentioned above. The 
combination of TBCA 10
-6
M and NET 10
-8
M, 10
-6
M reduced significantly the 
proliferation rate of MutB and WT-12. As shown before, E2 at various 
concentrations enhanced the proliferation of MutA, MutB and WT-12 cell (Fig. 17). 
However, MutC and EVC seemed not sensitive to E2. Addition of TBCA (10
-6
M) 
could reverse the effects of E2 on MutA at the E2 concentration 10
-10
M, on MutB at 
10
-12
M and 10
-10
M, and on WT-12 at all E2 concentrations that we tested. Figure 
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18 showed the results regarding GF. This experiment was designed to exclude the 
potential universal effect of TBCA. The results showed that GF could elicit 
increased cell proliferation of all MCF-7 cells, even for MutC cells. And the 
induction was not reversed by TBCA.   
Finally, the combination of TBCA and three different progestins was tested. As 
shown in Figure 19-21, MPA, DNG and LNG were all able to significantly trigger 
the cell proliferation of MutA, MutB and WT-12 at a higher concentration range. No 
effect of TBCA alone was observed. TBCA reversed the effect of MPA as well as 
LNG at the concentration of 10-6M on MutB cells significantly. And it also reversed 
the effect of DNG at the concentration of 10-6M on MutA, MutB and WT-12 cells 
significantly. 
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Figure 14. MCF-7 MutA, MutB, MutC, WT-12, and EVC cells were incubated with NET (10-6M) and TBCA (10-7M, 
10-6M, 10-5M and 10-4M) alone respectively, and in combination sequentially. Cell proliferation was measured 
after 6 days. Data were normalized to ethanol (10-3M) stimulated control cells. (Means±SD; *p < 0.05; **p < 
0.01 vs. NET alone). 
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Figure 15. MCF-7 MutA, MutB, MutC, WT-12, and EVC cells were incubated with E2 (10-12M, 10-10M) and TBCA 
(10-7M, 10-6M and 10-5M) alone respectively, and in combination sequentially. Cell proliferation was measured 
after 6 days. Data were normalized to ethanol (10-3M) stimulated control cells. (Means±SD; *p < 0.05; **p < 
0.01 vs. E2 alone). 
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Figure 16. MCF-7 MutA, MutB, MutC, WT-12, and EVC cells were incubated with TBCA (10-6M) and NET (10-
12M, 10-10M, 10-8M and 10-6M) alone respectively, and in combination sequentially. Cell proliferation was 
measured after 6 days. Data were normalized to ethanol (10-3M) stimulated control cells. (Means±SD; *p < 
0.05; **p < 0.01 vs. NET alone). 
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Figure 17. MCF-7 MutA, MutB, MutC, WT-12, and EVC cells were incubated with TBCA (10-6M) and E2 (10-14M, 
10-12M and 10-10M) alone respectively, and in combination sequentially. Cell proliferation was measured after 
6 days. Data were normalized to ethanol (10-3M) stimulated control cells. (Means±SD; *p < 0.05; **p < 0.01 vs. 
E2 alone). 
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Figure 18. MCF-7 MutA, MutB, MutC, WT-12, and EVC cells were incubated with TBCA (10-6M) and growth 
factors EGF, FGF and IGF-I 10-10M, 10-9M and 10-8M (GF 10-10M, 10-9M and 10-8M) alone respectively, and in 
combination sequentially. Cell proliferation was measured after 6 days. Data were normalized to ethanol (10-
3M) stimulated control cells. (Means±SD; *p < 0.05; **p < 0.01 vs. GF alone). 
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Figure 19. MCF-7 MutA, MutB, MutC, WT-12, and EVC cells were incubated with TBCA (10-6M) and MPA (10-
12M, 10-10M, 10-8M and 10-6M) alone respectively, and in combination sequentially. Cell proliferation was 
measured after 6 days. Data were normalized to ethanol (10-3M) stimulated control cells. (Means±SD; *p < 
0.05; **p < 0.01 vs. MPA alone). 
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Figure 20. MCF-7 MutA, MutB, MutC, WT-12, and EVC cells were incubated with TBCA (10-6M) and DNG (10-
12M, 10-10M, 10-8M and 10-6M) alone respectively, and in combination sequentially. Cell proliferation was 
measured after 6 days. Data were normalized to ethanol (10-3M) stimulated control cells. (Means±SD; *p < 
0.05; **p < 0.01 vs. DNG alone). 
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Figure 21. MCF-7 MutA, MutB, MutC, WT-12, and EVC cells were incubated with TBCA (10-6M) and LNG (10-
12M, 10-10M, 10-8M and 10-6M) alone respectively, and in combination sequentially. Cell proliferation was 
measured after 6 days. Data were normalized to ethanol (10-3M) stimulated control cells. (Means±SD; *p < 
0.05; **p < 0.01 vs. LNG alone). 
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3.2.4 Blocking effect of tamoxifen on the prolieferation of MCF-7 cells 
E2 and tamoxifen were used alone and in combination continuously or sequentially 
on MCF-7 MutA, MutB, MutC, WT-12 and EVC cells to determine the best manner. 
By continuous combined manner, it means that cells were incubated 6 days with 
E2 and tamoxifen combination. And by sequential manner, cells were treated 3 
days first by either E2 alone or tamoxifen alone, and then by E2 and tamoxifen 
combination for the next 3 days. The proliferation rate was measured after 6 days. 
As shown in Figure 22-24, tamoxifen alone at all concentrations did not trigger any 
increase of MCF-7 MutA, MutC and EVC proliferation, but enhanced slightly 
proliferation of MCF-7 MutB and WT-12 cells. When MCF-7 cells were stimulated 
with E2 plus tamoxifen continuously (Fig. 22), the proliferation of the proliferative 
effect caused by E2 on MutA, MutB and WT-12 could be significantly reduced. 
When the cells were previously treated by tamoxifen (Fig. 23), and then add E2 in 
the system, the reduction of E2-induced proliferation of MutA, MutB and WT-12 
cells was more obvious. However, when E2 was added first, no blocking effect was 
found (Fig. 24). 
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Figure 22. MCF-7 MutA, MutB, MutC, WT-12, and EVC cells were incubated with tamoxifen (10-9M, 10-8M, 10-
7M and 10-6M) and E2 (10-10M and 10-8M) alone respectively, and in combination continuously. Cell 
proliferation was measured after 6 days. Data were normalized to ethanol (10-3M) stimulated control cells. 
(Means±SD; *p < 0.05; **p < 0.01 vs. E2 alone). 
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Figure 23. MCF-7 MutA, MutB, MutC, WT-12, and EVC cells were incubated with tamoxifen (10-9M, 10-8M, 10-
7M and 10-6M) and E2 (10-10M and 10-8M) alone respectively, and in combination sequentially (tamoxifen alone 
for the first 3 days). Cell proliferation was measured after 6 days. Data were normalized to ethanol (10-3M) 
stimulated control cells. (Means±SD; *p < 0.05; **p < 0.01 vs. E2 alone). 
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Figure 24. MCF-7 MutA, MutB, MutC, WT-12, and EVC cells were incubated with tamoxifen (10-9M, 10-8M, 10-
7M and 10-6M) and E2 (10-10M and 10-8M) alone respectively, and in combination sequentially (E2 alone for the 
first 3 days). Cell proliferation was measured after 6 days. Data were normalized to ethanol (10-3M) stimulated 
control cells. (Means±SD; *p < 0.05; **p < 0.01 vs. E2 alone). 
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3.3 Western blot analysis 
MCF-7 MutA, MutB, MutC, WT-12, and EVC cells were incubated with NET (10
-6
M) 
alone and in combination with TBCA (10
-6
M) sequentially. After 120min, protein 
was extracted from cells. A western blot of equal total protein amounts (25µg/lane) 
was then performed. 
 
Figure 25. Western Blot analysis with phospho-PGRMC1-speciﬁc mouse 
monoclonal antibody 3G11A2. Upper panels depict loading controls for actin. 
Lower panels represent the expression of phosphorylated protein pS180. (+: 
TBCA 10-6M + NET 10-6M; -: NET 10-6M alone). 
As can be seen in Figure 25, because MutB, MutC were MCF-7 cells which was 
stably transfected with plasmid encoded by PGRMC1 mutation at the site S180A, 
no expression of pS180 was detected in both cell lines. Moreover, EVC is an 
empty vector control that was transfected with pcDNA3.1-3HA plasmid, so no 
expression of pS180 was found either. For MutA and WT-12, the expression of 
pS180 was detected. However, no significant difference regarding pS180 
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expression between NET alone and blocking with TBCA was found. This western 
blot experiment was also performed using E2 as the stimulation. And exact same 
result was observed (data not shown). 
3.4 Quantitative real-time PCR 
Quantitative real-time PCR (qRT-PCR) was used to measure expression of the 
endogenous estrogen responsive gene TFF1 in MCF-7 cells and T47D cells stably 
transfected with wild-type PGRMC1 or mutant PGRMC1 expression plasmids, after 
stimulation of either estrogen of progestins. 
3.4.1 Effect of E2 alone on transcription of TFF1 in MCF-7 and T47D cells  
TFF1 has been reported as an estrogen-responsive gene, whose mRNA 
expression can be induced by estrogen. Based on this theory, the first experiment 
was performed, using mRNA extracted from MCF-7 and T47D cells, which were 
incubated with E2 at various concentrations. 
 
Figure 26. MCF-7 WT-12, and EVC cells were incubated with E2 (10-10M, 10-9M 
and 10-8M) for 1h. After mRNA isolation and reverse transcriptase PCR, the 
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quantity of TFF1 cDNA in relation to the PDH cDNA was measured in the 
LightCycler System. The quantity of TFF1 cDNA in stimulated cells was 
normalized to ethanol (10-3M) stimulated control cells.   (Means±SD; *p < 0.05; 
**p < 0.01 vs. ethanol). 
 
Figure 27. T47D WT-3 and EVC cells were incubated with E2 (10-10M, 10-9M 
and 10-8M) for 1h. After mRNA isolation and reverse transcriptase PCR, the 
quantity of TFF1 cDNA in relation to the PDH cDNA was measured in the 
LightCycler System. The quantity of TFF1 cDNA in stimulated cells was 
normalized to ethanol (10-3M) stimulated control cells.   (Means±SD; *p < 0.05; 
**p < 0.01 vs. ethanol). 
As can be seen in Figure 26, 27, the TFF1 expression of both MCF-7 and T47D 
cells was indeed significantly up-regulated: for MCF-7 WT-12 cells at the 
concentration of 10
-9
M and 10
-8
M, for MCF-7 EVC at all the concentrations that we 
77 
 
tested, and for T47D WT-3 at the concentration of 10
-9
M, whereas T47D did not 
react to E2 stimulation. 
3.4.2 Time-dependent effect of E2 and NET on transcription of TFF1 in MCF-7 
and T47D cells 
Subsequently, a series of time-dependent experiments were performed. We 
treated MCF-7 and T47D cells with E2 (10-8M, 10-9M) and NET (10-7M) alone, 
respectively, for 0.5h, 1h, 2h and 4h. The different time periods allowed us to 
assess rapid, direct transcriptional effects as well as more delayed, potentially 
secondary effects. 
Both E2 and NET triggered a significant increase of TFF1 expression in MCF-7 
WT-12 cells after an incubation time of 0.5h, but not in EVC cells (Fig. 28, 29). 
After 1h, the stimulation for WT-12 and also EVC resulted in significantly elevated 
activation of TFF1. A similar effect was observed in MCF-7 WT-12 and EVC cells 
after 2h incubation. However, EVC cells did not react to NET 10-7M. After 4h, NET 
was able to significantly elevate the expression of TFF1 in WT-12 cells, but not 
EVC cells. And E2 elicited significantly the expression of TFF1 in WT-12 cells only 
at the concentration of 10-9M.  
For T47D cells, the exact same experiment was performed as it for MCF-7 cells. 
As can be seen in Figure 30 and 31, T47D WT-3 and EVC cells did not result in 
any significant up-regulation of TFF1 expression after 0.5h incubation. However, 
after a longer incubation time, namely 1h, 2h and 4h, both E2 and NET were able 
to trigger a significant increase of TFF1 expression in WT-3. As for T47D EVC cells, 
except E2 at the concentration of 10-9M, no significant increase of TFF1 expression 
was found. 
Obviously, with regard to estrogen or progestins triggering the up-regulation of 
TFF1 expression, the incubation time of 1h was more sensitive for both MCF-7 and 
T47D cells. Hence, this time period was chosen for further experiments.    
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Figure 28. MCF-7 WT-12 and EVC cells were incubated with E2 (10-8M) and NET (10-7M) alone respectively for 
0.5h, 1h, 2h and 4h. After mRNA isolation and reverse transcriptase PCR, the quantity of TFF1 cDNA in 
relation to the PDH cDNA was measured in the LightCycler System. The quantity of TFF1 cDNA in stimulated 
cells was normalized to ethanol (10-3M) stimulated control cells.   (Means±SD; *p < 0.05; **p < 0.01 vs. 
ethanol). 
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Figure 29. MCF-7 WT-12 and EVC cells were incubated with E2 (10-9M) and NET (10-7M) alone respectively for 
0.5h, 1h, 2h and 4h. After mRNA isolation and reverse transcriptase PCR, the quantity of TFF1 cDNA in 
relation to the PDH cDNA was measured in the LightCycler System. The quantity of TFF1 cDNA in stimulated 
cells was normalized to ethanol (10-3M) stimulated control cells.   (Means±SD; *p < 0.05; **p < 0.01 vs. 
ethanol). 
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Figure 30. T47D  WT-3 and EVC cells were incubated with E2 (10-8M) and NET (10-7M) alone respectively for 
0.5h, 1h, 2h and 4h. After mRNA isolation and reverse transcriptase PCR, the quantity of TFF1 cDNA in 
relation to the PDH cDNA was measured in the LightCycler System. The quantity of TFF1 cDNA in stimulated 
cells was normalized to ethanol (10-3M) stimulated control cells.   (Means±SD; *p < 0.05; **p < 0.01 vs. 
ethanol). 
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Figure 31. T47D  WT-3 and EVC cells were incubated with E2 (10-9M) and NET (10-7M) alone respectively for 
0.5h, 1h, 2h and 4h. After mRNA isolation and reverse transcriptase PCR, the quantity of TFF1 cDNA in 
relation to the PDH cDNA was measured in the LightCycler System. The quantity of TFF1 cDNA in stimulated 
cells was normalized to ethanol (10-3M) stimulated control cells.   (Means±SD; *p < 0.05; **p < 0.01 vs. 
ethanol). 
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3.4.3 Effect of progestogens alone on transcription of TFF1 in MCF-7 and 
T47D cells  
Since the elevated activation of TFF1 triggered by NET was detected, it would be 
really interesting for us to test the possible effects of other synthetic progestins. 
Therefore, we investigated first NET at various concentrations.  
 
Figure 32. MCF-7 WT-12 and EVC cells were incubated with NET (10-8M, 10-
7M and 10-6M) alone for 1h. After mRNA isolation and reverse transcriptase 
PCR, the quantity of TFF1 cDNA in relation to the PDH cDNA was measured 
in the LightCycler System. The quantity of TFF1 cDNA in stimulated cells was 
normalized to ethanol (10-3M) stimulated control cells.   (Means±SD; *p < 0.05; 
**p < 0.01 vs. ethanol). 
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Figure 33. T47D WT-3 and EVC cells were incubated with NET (10-8M, 10-7M 
and 10-6M) alone for 1h. After mRNA isolation and reverse transcriptase PCR, 
the quantity of TFF1 cDNA in relation to the PDH cDNA was measured in the 
LightCycler System. The quantity of TFF1 cDNA in stimulated cells was 
normalized to ethanol (10-3M) stimulated control cells.   (Means±SD; *p < 0.05; 
**p < 0.01 vs. ethanol). 
NET at the concentration of 10-7M triggered significantly the increase of TFF1 
transcription level in MCF-7 WT-12, EVC, and T47D WT-3 cells (Fig. 32, 33). 
However, the transcription of TFF1 in T47D EVC cells did not alter significantly 
alter the NET stimulation compared with ethanol (10-3M) stimulated control cells. 
Moreover, other concentrations of NET, even if it is higher than 10-7M, could not 
cause any elevation of TFF1 expression.    
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Figure 34. MCF-7 WT-12 and EVC cells were incubated with DSP (10-8M, 10-7M 
and 10-6M) alone for 1h. After mRNA isolation and reverse transcriptase PCR, 
the quantity of TFF1 cDNA in relation to the PDH cDNA was measured in the 
LightCycler System. The quantity of TFF1 cDNA in stimulated cells was 
normalized to ethanol (10-3M) stimulated control cells.   (Means±SD; *p < 0.05; 
**p < 0.01 vs. ethanol). 
Another synthetic progestin, DSP, which were commonly used clinically, was then 
tested. Additionally, E2 10-9M was also used as a quality control of the experiment. 
Consistently, the stimulation of E2 alone on MCF-7 WT-12, EVC and T47D WT-3 
cells triggered significant increase of TFF1 transcription. It could represent the 
promising results of this experiment. As can be seen in Figure 34, 35, DSP elicited 
increased TFF1 expression in MCF-7 WT-12, EVC and T47D WT-3 cells only at 
the highest concentration that we tested. And T47D EVC cell reacted to neither E2 
nor DSP stimulation. 
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Figure 35. T47D WT-3 and EVC cells were incubated with DSP (10-8M, 10-7M 
and 10-6M) alone for 1h. After mRNA isolation and reverse transcriptase PCR, 
the quantity of TFF1 cDNA in relation to the PDH cDNA was measured in the 
LightCycler System. The quantity of TFF1 cDNA in stimulated cells was 
normalized to ethanol (10-3M) stimulated control cells.   (Means±SD; *p < 0.05; 
**p < 0.01 vs. ethanol). 
Furthermore, P4 and other progesins were tested, including MPA, NOM and CMA. 
As can be seen in Figure 36, P4, MPA and CMA at the concentration of 10-7M 
were not able to result in any elevated activation of TFF1. Among all the progesting 
that we tested, only NOM at the concentration of 10-7M enhanced the transcription 
of TFF1 in both MCF-7 WT-12 and T47D WT-3 cells. This effect of NOM is similar 
to the effect of NET (Fig. 37), except that MCF-7 EVC cells react to NET but not 
NOM. 
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Figure 36. MCF-7 and T47D cells were incubated with P4, NOM, MPA and CMA at the concentration of 10-7M 
for 1h. After mRNA isolation and reverse transcriptase PCR, the quantity of TFF1 cDNA in relation to the PDH 
cDNA was measured in the LightCycler System. The quantity of TFF1 cDNA in stimulated cells was 
normalized to ethanol (10-3M) stimulated control cells.   (Means±SD; *p < 0.05; **p < 0.01 vs. ethanol). 
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Figure 37. MCF-7 WT-12 cells were incubated with NET, NOM and MPA at the 
concentration of 10-7M for 1h. After mRNA isolation and reverse transcriptase 
PCR, the quantity of TFF1 cDNA in relation to the PDH cDNA was measured 
in the LightCycler System. The quantity of TFF1 cDNA in stimulated cells was 
normalized to ethanol (10-3M) stimulated control cells.   (Means±SD; *p < 0.05; 
**p < 0.01 vs. ethanol). 
3.4.4 Effect of estrogen plus progestogens on transcription of TFF1 in MCF-7 
cells  
In this study, we have already proved that estrogens as well as progestogens 
alone can trigger statistically significant induction of TFF1 transcription. Therefore, 
for further investigation, the effect of the combination of estrogen and different 
progestogens was detected. As can be seen in Figure 38, the transcriptional level 
of TFF1 gene was significantly elevated not only by E2 and NET alone respectively, 
but the combination of E2 and NET elicited a similar up-regulation. Moreover, 
although P4, as a neutral progestogen, would not trigger any increase of TFF1 
expression, with combination of E2 enhanced significantly the transcription of TFF1. 
However, no significant differences of the proliferation rate was detected between 
NET/E2 alone and NET plus E2. 
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Figure 38. MCF-7 WT-12 and EVC cells were incubated with P4 (10-7), NET (10-
7M), E2 (10-9) alone respectively, or in combination for 1h. After mRNA 
isolation and reverse transcriptase PCR, the quantity of TFF1 cDNA in 
relation to the PDH cDNA was measured in the LightCycler System. The 
quantity of TFF1 cDNA in stimulated cells was normalized to ethanol (10-3M) 
stimulated control cells.   (Means±SD; *p < 0.05; **p < 0.01 vs. ethanol). 
3.4.5 Blocking effect of fulvestrant on transcription of TFF1 in MCF-7 and 
T47D cells  
A selective estrogen receptor modulator was then investigated in the blocking 
experiment. Unlike NET, fulvestrant was dissolved in DMSO, therefore, three 
different controls were applied in this experiment: ethanol (10-3M) as the control of 
NET alone, DMSO (10-3M) as the control of fulvestrant alone, and ethanol (10-3M) 
plus DMSO (10-3M) as the control of the combination of NET and fulvestrant. 
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Figure 39 and 40 exhibited the up-regulation of TFF1 expression triggered by NET, 
as well as the suppression of it caused by fulvestrant in MCF-7 WT-12, EVC and 
T47D WT-3 cells. However, T47D EVC cells did not show the similar down-
regulation in the presence of fulvestrant. Again, MCF-7 MutC cells did not react to 
any stimulation. 
 
Figure 39. MCF-7 MutC, WT-12 and EVC cells were incubated with fulvestrant 
10-6M and NET 10-7M alone respectively, or in combination for 1h. After 
mRNA isolation and reverse transcriptase PCR, the quantity of TFF1 cDNA in 
relation to the PDH cDNA was measured in the LightCycler System. The 
quantity of TFF1 cDNA in stimulated cells was normalized to ethanol (10-3M), 
DMSO (10-3M) or ethanol plus DMSO (10-3M) stimulated control cells 
respectively.   (Means±SD; *p < 0.05; **p < 0.01 vs.NET alone). 
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Figure 40. T47D WT-3 and EVC cells were incubated with fulvestrant 10-6M 
and NET 10-7M alone respectively, or in combination for 1h. After mRNA 
isolation and reverse transcriptase PCR, the quantity of TFF1 cDNA in 
relation to the PDH cDNA was measured in the LightCycler System. The 
quantity of TFF1 cDNA in stimulated cells was normalized to ethanol (10-3M), 
DMSO (10-3M) or ethanol plus DMSO (10-3M) stimulated control cells 
respectively.   (Means±SD; *p < 0.05; **p < 0.01 vs.NET alone). 
3.4.6 Blocking effect of AG205 on transcription of TFF1 in MCF-7 and T47D 
cells 
Furthermore, another blocking experiment regarding TFF1 transcription was 
performed on MCF-7 and T47D cells. Unlike NET, AG205 was dissolved in DMSO, 
therefore, three different controls were applied in this experiment: ethanol (10-3M) 
as the control of NET alone, DMSO (10-3M) as the control of AG205 alone, and 
ethanol (10-3M) plus DMSO (10-3M) as the control of the combination of NET and 
AG205.  
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Figure 41. MCF-7 MutC, WT-12 and EVC cells were incubated with AG205 10-
6M and NET 10-7M alone respectively, or in combination for 1h. After mRNA 
isolation and reverse transcriptase PCR, the quantity of TFF1 cDNA in 
relation to the PDH cDNA was measured in the LightCycler System. The 
quantity of TFF1 cDNA in stimulated cells was normalized to ethanol (10-3M), 
DMSO (10-3M) or ethanol plus DMSO (10-3M) stimulated control cells 
respectively.   (Means±SD; *p < 0.05; **p < 0.01 vs.NET alone). 
Figure 41 and 42 demonstrated that in both PGRMC1 wild-type plasmid 
transfected cell line, MCF-7 WT-12 and T47D WT-3, the NET-regulated increase of 
TFF1 transcription was fully reversed in the presence of AG205. However, no 
significant down-regulation was observed in EVC transfected MCF-7 and T47D 
cells. Again, MCF-7 MutC cells did not react to any stimulation. 
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Figure 42. T47D WT-3 and EVC cells were incubated with AG205 10-6M and 
NET 10-7M alone respectively, or in combination for 1h. After mRNA isolation 
and reverse transcriptase PCR, the quantity of TFF1 cDNA in relation to the 
PDH cDNA was measured in the LightCycler System. The quantity of TFF1 
cDNA in stimulated cells was normalized to ethanol (10-3M), DMSO (10-3M) or 
ethanol plus DMSO (10-3M) stimulated control cells respectively.   (Means±SD; 
*p < 0.05; **p < 0.01 vs.NET alone). 
3.4.7 Blocking effect of TBCA on transcription of TFF1 in MCF-7 cells  
As mentioned above, TBCA was used as an inhibitor to block the 
estrogens/progestins-triggered proliferative effect. In the next step of our 
experiment, the same blocking experiment was also used to measure the variation 
of the transcription level of TFF1 in MCF-7 cells.  
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Figure 43. MCF-7 MutC, WT-12 and EVC cells were incubated with TBCA 10-
6M and NET 10-7M alone respectively, or in combination for 0.5h. After mRNA 
isolation and reverse transcriptase PCR, the quantity of TFF1 cDNA in 
relation to the PDH cDNA was measured in the LightCycler System. The 
quantity of TFF1 cDNA in stimulated cells was normalized to ethanol (10-3M) 
stimulated control cells.   (Means±SD; *p < 0.05; **p < 0.01 vs. ethanol). 
As can be seen in Figure 43, 44, TBCA did not induce or reduce the transcription 
of TFF1 in all the MCF-7 cell lines, whereas NET and E2 triggered consistently the 
elevation of TFF1 expression. Compared with NET or E2 alone respectively, the 
combination of NET plus TBCA and E2 plus TBCA reversed the up-regulation of 
TFF1 transcription in MCF-7 WT-12 cells completely, but not in EVC cells. We also 
included MCF-7 MutC cells in this experiment. However, no significant up-or down-
regulation of TFF1 expression was detected. 
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Figure 44. MCF-7 MutC, WT-12 and EVC cells were incubated with TBCA 10-
6M and NET 10-7M alone respectively, or in combination for 1h. After mRNA 
isolation and reverse transcriptase PCR, the quantity of TFF1 cDNA in 
relation to the PDH cDNA was measured in the LightCycler System. The 
quantity of TFF1 cDNA in stimulated cells was normalized to ethanol (10-3M) 
stimulated control cells.   (Means±SD; *p < 0.05; **p < 0.01 vs.NET/E2 alone). 
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4 DISCUSSION 
4.1 The effect of estrogen/progesterone on breast cancer cell proliferation 
4.1.1 Proliferative effect of progestogens on breast cancer cells  
For the past few years we have been performing in vitro experiments with MCF-7 
cells overexpressing PGRMC1. At first, we showed in functional studies (Neubauer 
et al. 2009) that progesterone conjugated with BSA-FITC, which is membrane-
impermeable, was able to increase the proliferation of MCF-7/PGRMC1 cells by 
36% independent of the classical progesterone receptor. Unconjugated 
progesterone did not show any effect. In 2008, this work was awarded with a 
special prize for breast cancer research at the World Congress on Menopause in 
Madrid. In addition, this progesterone complex was able to increase the mRNA 
level of vascular endothelial growth factor A (VEGF-A) three-fold as compared to 
control cells (Neubauer et al. 2009).  
These in vitro results correlate with in vivo studies by Peluso and colleagues 
(Peluso et al. 2009) using a mouse model with PGRMC1 expressing SKOV-3 
ovarian cancer cells and PGRMC1-depleted SKOV-3. The microvasculature of 
tumors established by transplanted PGRMC1-depleted cells was only 14% of that 
of tumors derived from parental SKOV3-cells. In glia cells of the retina, 
progesterone also stimulated the VEGF expression (Swiatek-De et al. 2007). 
In the present study, we tested the main progestins used for hormone therapy or 
contraception such as the synthetic progestins chlormadinone acetate (CMA), 
desogestrel (DSG), dienogest (DNG), drospirenone (DSP), dydrogesterone (DYD), 
levonorgestrel (LNG), medroxyprogesterone acetate (MPA) used in the Women‟s 
Health Initiative (WHI) study (Rossouw et al. 2002), nomegestrol (NOM) and 
norethisterone acetate (NET) reported in the Million Women Study (WMS) in UK 
(Beral et al. 2003) as well as the natural progesterone (P4) applied in the French 
E3N cohort study (Fournier et al. 2008). Since small modifications of their chemical 
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structure could change their property to proliferate breast cancer cells. In addition, 
we applied for the first time a new cell model, T47D, which was also stably 
transfected with the same PGRMC1-WT and empty vector plasmids. 
As shown above, for the MCF-7 cell model, P4 and NOM act neutrally, whereas 
DNG, MPA, LNG and NET increase cell proliferation and thus may increase breast 
cancer risk. The actual results confirm our previous ones that NET is the progestin 
resulting in  the strongest proliferative effects on WT-12 cells,  and DNG, DYD and 
MPA were active only at the highest concentration tested (10-6M), whereas P, CMA 
and NOM had no significant effect.( Ruan et al. 2012). 
These differences can probably be aligned with the two different structural 
deviations: progestins are structurally related to testosterone (DNG and NET) as 
well as MPA, a pregnane derivative with androgenic properties, and acting 
proliferative, whereas progesterone and progesterone-related progestins (CMA 
and NOM) were neutral with the exception of DYD. The reason for this discrepancy 
is not known so far. Perhaps the effective metabolite dihydrodydrogeterone may be 
informative. DSP, a derivative of spirolactone, also displays a strong proliferative 
effect. 
For the first time, another cell model T47D was included in this study. The 
proliferative effect of progestogens on T47D wild-type cells (WT-3) was similar to 
the results of MCF-7 wild-type cells (WT-12). However, in this experiment, CMA 
also triggered a relatively low, yet significant proliferative effect at both 
concentrations tested (10-7M, 10-6M). Interestingly, as control, T47D EVC and 
untransfected T47D cells appeared to be more sensitive to various progestins 
compared with MCF-7 control cells. Even P4 and NOM, which was total neutral in 
the MCF-7 model, had significant effect on T47D EVC and transfected T47D cells. 
Due to the exact same condition of these two experiment (including incubation time 
period, dissolution of progestogens, detective method, etc.), the distinction may 
arise only from the individual differences of MCF-7 and T47D. 
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T47D and MCF7 are two human hormone-dependent breast cancer cell lines 
which are widely used as experimental models for breast cancer studies. They 
were both originally derived from a metastatic site of pleural effusion (ATCC, 
www.atcc.org) and express estrogen receptors. Aka and colleges (Aka et al. 2012) 
reported that more than 164 proteins are differentially expressed between them. 
Specifically, Proteins involved in cell growth stimulation, anti-apoptosis 
mechanisms and cancerogenesis are more strongly expressed in T47D than in 
MCF7. These proteins include G1/S-specific cyclin-D3 and prohibitin. Proteins 
implicated in transcription repression and apoptosis regulation, including 
transcriptional repressor NF-X1, nitrilase homolog 2 and interleukin-10, are, on the 
contrary, more strongly expressed in MCF7 as compared to T47D. 
4.1.2 Proliferative effect of estrogens on breast cancer cells  
Although estrone (E1), estradiol (E2), estrol (E3) and estetrol (E4) are all 
endogenous estrogens, the functions of them are disparate: Estradiol (E2) is the 
predominant estrogen during reproductive years both in terms of absolute serum 
levels as well as in terms of estrogenic activity. When a woman is pregnant, estriol 
(E3) is the predominant estrogen, which replaces estradiol (E2). Estetrol (E4) is 
only produced only during pregnancy by the fetal liver. When a woman reaches 
menopause, estrone (E1), a weaker form of estrogen, becomes predominant. 
Estradiol (E2) is the strongest of estrogens and available before menopause or 
pregnancy (Coelingh et al. 2008; Holinka et al. 2008; Ingle et al. 2014). E2 is still 
the most frequently used estrogen in menopausal hormone therapy (MHT) for 
postmenopausal women, as reported by many observational studies and 
randomized controlled trials, including in the Million Women Study (WMS) (Beral et 
al. 2003), whereas conjugated equine estrogens (CEE) was used in the WHI 
hormone therapy trials (Rossouw et al. 2002). CEE is a mixture of estrogens 
isolated from horse urine. Two of the major components of CEE are E1 (52.5-
61.5%) and equilin (22.5-30.5%). E1 can be normally found in women; However 
Equilin is not, so there has been interest in the effects of equilin on the human 
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body (Sawicki et al. 1999). There also other Concomitants in CEE, such as 17α-
Dihydroequilin (13.5-19.5%) and 17β-Dihydroequilin. Ethinyl estradiol (EE) is a 
derivative of E2, which is an orally bioactive estrogen used in many formulations of 
combined oral contraceptive pills. It is one of the most commonly used medications 
for this purpose. 
Regarding the proliferative effect of different estrogens on MCF-7 cells, the 
following interesting results were observed in our study. Estrone (E1), estradiol 
(E2), estrol (E3), estetrol (E4), ethinyl estradiol (EE) and equilin (Eq) are able to 
increase cell proliferation in a concentration-dependent fashion. Only 17α-
Dihydroequilin was inactive. At the lowest concentration of 10-12M, E1, E2, E3 and 
E4 had no effect whereas EE and Eq significantly increased the proliferation rate. 
At the highest concentration 10-9 M, all these estrogens acted proliferatively. As for 
control cells, MCF-7 EVC and untransfected MCF-7 cells did not demonstrated 
significant elevation. And again, for T47D WT-3 cells, a similar increase of 
proliferation after stimulation of various estrogens was observed. Even T47D EVC 
and untransfected T47D cells exhibited a low yet significant dose-dependent 
enhanced proliferation. 
These results showed that the estrogenic effect on MCF-7 WT as well as T47D WT 
cells is clearly dose-dependent. E1, E2, E3, E4, EE and Eq elicited a significant 
increase in cell proliferation only at higher concentration (10-10M). Thus choosing a 
low-dose oral or transdermal administration may be of importance in the presence 
of PGRMC1. However, the other publication demonstrated the opposite. Gérard  
and colleges revealed that E4 was 100 times less potent than E2 to stimulate the 
proliferation of human breast epithelial (HBE) cells. In addition, E4 exhibits 
antagonistic properties towards the proliferative effect of E2 on breast epithelial 
cells (Gérard et al. 2014). 
Furthermore, in comparison to breast cancer cell lines overexpressing PGRMC1, 
the stimulation of estrogens did not or did only induce low proliferation rate of the 
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empty vector control cell lines, which may suggest that PGRMC1 enhances the 
sensitivity of breast cancer cells towards a strong estrogenic proliferative effect via 
an interaction of PGRMC1 and ERα. 
4.1.3 Proliferative effect of progestogens/estrogens combination on breast 
cancer cells  
The role of progestogen addition to estrogen therapy in the postmenopause has 
come under scrutiny since the results of the Women‟s Health Initiative (WHI) 
estrogen-only arm were published as compared to the WHI combined arm 
(Rossouw et al. 2002; Anderson et al. 2004). In comparison to the estrogen-only 
arm, in which a reduction of breast cancer risk was observed, in the combined arm 
increase of breast cancer risk was found. The French E3N cohort study has 
reported, using micronized progesterone in combination with estrogens, no 
increase in breast cancer risk when combining transdermal (patches) or 
percutaneous (gels) estradiol therapy with progesterone (Fournier et al. 2008). In 
80377 women, breast cancer risk was increase with oral synthetic progestins, but 
not with progesterone and dydogesterone. 
Consistent with our previous studies, we found in the present study that the 
addition of progestins to high concentration of E2 (10-10M) does not influence the 
estradiol-induced MCF-7 proliferative. However, when adding the progestins to 
lower concentrations of E2 (10-14M, 10-12M), all progestins were effective in eliciting 
a proliferative effect as a mono substance also increased the proliferation, and 
NET showed the greatest effect. However, when we include another estrogen, EE, 
in this experiment and raise the concentration to 10-10M and 10-9M, the 
combination of EE and CYP, DSP, LNG and NET can still elicit significantly 
proliferation of MCF-7 WT-12 cells, which proved again that various estrogens and 
progestogens function differently. 
Moreover, for the newly transfected T47D cells, the sensitivity was obviously higher 
than the MCF-7 cells. Significant increase of proliferation was found even in the 
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control cells T47D EVC. Interestingly, for the MCF-7 cells, no proliferative effect 
was elicited by CMA, NOM and P4, which were proved to be neutral in breast 
cancer risk when combined with E2, at least in women overexpressin PGRMC1. 
However, except P4, the combination of E2 with both CMA and NOM elicited 
significant increased proliferation of T47D WT-3 cells.  
These effects was more pronounced in the continuous combined treatment than in 
the sequential therapy, i.e. 6 days combined treatment than the sequential therapy 
versus 3 days estrogens alone plus 3 days estrogen plus progestin. Collectively, 
results from this study provided evidence at the molecular level that differing 
regimens of menopausal hormone therapy (MHT) can cause disparate 
consequences. It would imply that the common regimen of continuous combined 
MHT may have adverse consequences whereas a sequential regimen, which is 
more physiological, could be an effective strategy to maintain health and function 
throughout menopausal aging. 
At least for a sequential E2/NET combination, these data have been validated in 
the meantime in in vitro experiments by transplanting MCF-7/PGRMC1 cells in a 
mouse model developed by Dr S. Hyder (Liang et al. 2007). In this mouse model, 
MCF-7/PGRMC1-inoculated cells were more sensitive towards estradiol and 
elicited a stronger proliferative response in the presence of NET as compared to 
MCF-7 cells containing the vector control (Neubauer et al. 2013) 
In summary, the data presented are very important in terms of the positive results 
of MHT and breast cancer risk in clinical studies so far. They provided an in vitro 
model that is able to explain the positive effect of MHT on breast cancer 
tumorigenesis. Furthermore, this effect may depend on the specific chemical 
structure and various preparations of MHT.  
4.1.4 Phosphorylation site mutants of PGRMC1 affect cell proliferation 
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Protein motifs prediction for PGRMC1 revealed that each phosphorylation site was 
contained within known kinase recognition motifs (Table 2). P180 and T160 are 
present within consensus binding sites for ERK1 and PDK1, respectively. S56 and 
S180 are present within a consensus sequence for acidophilic kinase CK2 
phosphorylation. And it also includes two SH2 target sequences (Y138, Y179), one 
SH3 target sequence (P62), and a tyrosine kinase site (Y112).  
Since PGRMC1 contains several sites for phosphorylation, we transfected MCF-7 
cells each of the PGRMC1 expression plasmids (Table 5), in which specific 
position is modified, namely MutA (S56A), MutB (S180A), MutC (S56A/S180A), 
WT-12 (wild-type) and EVC (empty vector) and established stable transfected cell 
lines. Expression of exogenous PGRMC1 was confirmed in all cell lines using an 
anti-HA tag antibody.  
Unequal effects of estrogen/progestrogens on proliferation of various MCF-7 cells 
were detected in the present study. Cells with mutants on both N-terminal putative 
CK2 site (S56) and C-terminal CK2 site (S180), i.e. MutC, did not response to any 
stimulation. Because in MutC cells, the amino acid serine at position 56 and 180 is 
modified so that PGRMC1 cannot be phosphorylated by a kinase, which correlates 
with the assumption that phosphorylation of these sites may activate PGRMC1. By 
contrast, MutA and MutB cells showed practically the same increase of proliferation, 
compared with WT-12 cells, after stimulation of estrogens or progestrogens, which 
may suggest phosphorylation at only one of the site, i.e. S56 or S180, inactivates 
the receptor.   
Similar result was detected in one previous study. Neubauer and colleges 
(Neubauer et al. 2008) found, using the same cell model, that the degree of 
viability was greatly impaired in the presence of the H2O2 for all cell lines except 
the S56A/S180A double mutant. The expression of PGRMC1 double mutant 
substantially reduced the sensitivity of cells to H2O2 stress, resulting in higher cell 
viability. The possible mechanism of survival of the S56A/S180 mutant deserves 
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some consideration. Phosphorylation of S56 presumably blocks phosphorylation of 
the interaction of PGRMC1 with another protein(s) through the predicted proline-
rich SH3 target domain centered on P62, whereas phosphorylation of S181 
presumably blocks phosphorylation of the adjacent Y179, which would be 
necessary for interaction with one or more presumed SH2-domain proteins (Cahill. 
2008) Phosphorylation at certain site of may play a critical role in tumorigenesis 
mediated by hormone and may alter breast cancer risk in postmenopause women. 
4.2 A potential kinase correlated with PGRMC1 phosphorylation, CK2  
Protein kinase CK2 (official acronym for casein kinase 2 or II) is involved in cell 
proliferation and survival, and found overexpressed in virtually all types of human 
cancer, including breast cancer. Results from Neubauer and colleges (Neubauer et 
al. 2008) revealed that PGRMC1 is more abundant in ERα-negative tumors, but is 
more highly phosphorylated in ERα-positive tumors. Both acceptor serines of the 
predicted CK2 sites have been detected as phosphoserine peptides in PGRMC1 
from HeLa cell nuclear extracts (Beausoleil et al. 2004). S180 was also detected in 
PGRMC1 from human mitotic spindle preparations (Sauer et al. 2005), and from a 
trypsin digest of total mouse liver protein extract (Jin et al. 2004). Because 
phosphorylated peptides are notoriously difﬁcult to detect, it is possible that S56 
was phosphorylated in all those samples. Moreover, it has also recently been 
demonstrated that several tamoxifen resistant breast cancer cell lines showed 
greater susceptibility to apoptosis upon inhibition of CK2 compared to tamoxifen 
sensitive MCF-7 cells (Yde et al. 2007). 
Several lines of evidence suggested that CK2 is a potent suppressor of apoptosis 
in response to diverse apoptotic stimuli-thus its molecular down-regulation or 
activity inhibition results in potent induction of cell death (Qaiser et al. 2014). CK2 
inhibition in cells causes rapid early decrease in mitochondrial membrane potential 
(Δψm), which may be a primary trigger for apoptotic signaling and cell death. Yao 
and colleges (Yao et al. 2007) also observed that a synthetic highly selective CK2 
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inhibitor, tetra-bromo-cinnamic acid (TBCA), could reduce prostate cancer cell 
proliferation in a dose-dependent manner resulting from CK2 inhibition. However, 
in our study, TBCA alone appeared to have no effect on MCF-7 cell lines which did 
not receive any hormone stimulation. Although TBCA reversed, not fully yet 
significantly, the proliferation of several cell lines triggered by E2 and NET, no 
dose-dependent effect in the titration experiment was detected. To ensure these 
results, the possible universal effect of TBCA was also excluded by using GF as 
the stimulation. In summary, all our data strongly suggest that CK2 was correlated 
with the hormone-induced proliferation of breast cancer cells, and the inhibition of 
CK2 greatly undermined this effect. 
Interestingly, the reductive effect of TBCA appeared unequally on different 
PGRMC1 mutants: the proliferative effect of NET cannot be blocked in MutA cells, 
but can be reversed in MutB and WT-12 cells when NET was at a higher 
concentration range (10-8M, 10-6M), and with respect to E2-induced proliferation, 
the reductive effect of TBCA was clearly stronger. A study from Williams and 
colleges (Williams et al. 2009) revealed that estrogen receptor α (ERα) contains 
also several putative phosphorylation sites, and identified protein kinase CK2 as a 
kinase that phosphorylated two of them, i.e. S282 and S559 using motif analysis, in 
vitro kinase assays, and incubation of cells with CK2 kinase inhibitor. Therefore we 
conjecture that, if CK2 phosphorylated PGRMC1 and ERα simultaneously, the 
inhibition of phosphorylation on ERα may enhance the reduction of cell proliferation 
caused by inhibition of phosphorylation on PGRMC1, resulting in an unequal 
suppression of TBCA. However, E2 and NET are actually two different hormone 
components, thus, direct comparisons are inappropriate. Supposedly, this unequal 
effect could also be caused by the unpaired concentrations of E2 and NET. 
To further demonstrate the involvement of CK2 in the phosphorylation of PGRMC1 
and whether the phosphorylation of PGRMC1  was regulated by hormones, MCF-7 
WT-12 and mutants were pretreated with TBCA, followed with E2 or NET, cell 
lysates were then subjected to western blot using a phosphor-specific PGRMC1 
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antibody (pS180). This antibody provides a tool to validate the phosphorylation site 
S180 and to begin to assess the functional significance of this site.  
PGRMC1 in MutA and WT-12 cells was intact at the site of S180A. Thus, a strong 
phosphorylation at S180 was observed in these cells. The result suggests that the 
stimulation of NET did indeed lead to phosphorylation of PGRMC1 at the site S180. 
Additionally, the stimulation of E2 also phosphorylated PGRMC1 at the same site, 
which may extend the knowledge of the mechanism of E2-regulated breast cancer 
cell proliferation. However, TBCA did not suppress phosphorylation of s180a in 
MutA and WT-12 cells indicating that CK2 may not be responsible for the 
phosphorylation of S180 of PGRMC1. The western blot data was unexpected and 
completely contrary to our assumption. It is possible that other acidophilic kinase 
was involved, so identifying the right kinase for the phosphorylation of PGRMC1 
will be an interesting future direction of the research. However, the experiment was 
performed only once, thus, the inaccuracy should also be taken under 
consideration.  
4.3 Cross-talk between PGRMC1 and ER 
4.3.1 Tamoxifen blocks the proliferative effect of E2 
Recently, an increasing number of studies have found that estrogen can exert its 
action through not only the traditional genomic but also an extranuclear estrogen 
receptor (ER) pathway (Irsik et al. 2013; Levin. 2009). And also for many actions of 
progesterone, besides the intracellular transcription factors, i.e. PR-A and PR-B, a 
rapid, cell surface-mediated action is also involved (Revelli et al. 1998; Norman et 
al. 2004; Thomas. 2012). The extranuclear estrogen receptor includes membrane-
associated receptors and cytoplasmic receptor (Lappano et al. 2013). Because 
estrogen receptor (ER) has no intrinsic transmembrane domain and/or kinase 
domain, the cytoplasmic ER requires association-proteins to translocate it to the 
plasma membrane and trigger the cytoplasmic pathway. The extranuclear ER 
pathway is involved in several crucial cellular functions such as cell proliferation, 
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migration, secretion, and apoptosis (Bolli et al 2011; Cortez et al. 2010). 
Knowledge on these novel estrogen actions is now significantly broadening our 
understanding of breast carcinogenesis, particularly regarding metastasis and drug 
resistance (Chakravarty et al. 2010; Williams et al. 2013). However, mechanisms 
underlying rapid extranuclear responses of estrogen signal are not yet fully 
understood (Williams et al. 2013; Acconcia and Marino. 2011). 
Data from the present study demonstrated that E2 induced a rise in the 
proliferation rate of PGRMC1-overexpressing MCF-7 cell line. And this E2 –
regulated proliferative effect could be fully reversed in PGRMC1-overexpressing 
MCF-7 cell line, but not EVC control cells, when the cells were pretreated by 
tamoxifen, an antagonist of ER in breast tissue, at a higher concentration. This 
may suggest an involvement of PGRMC1 in the estrogen-regulated ER signaling 
pathway. Our previous studies also showed that the presence of ERα is mandatory 
for the observed proliferative effect, since only fulvestrant was able to totally block 
the proliferative effect of an estradiol/norethisterone combination (Ruan et al. 2012). 
Thus, the effect of progestogens appears to be mediated not only via the classical 
genomic pathway involving nuclear receptors (PRs) but also including non-nuclear 
receptors such as PGRMC1 which may act via a cross-talk with the nuclear or the 
extranuclear ER receptor. In addition, the similar blocking effect of tamoxifen was 
also detected in PGRMC1 mutants, namely, MutA and MutB, but not in MutC. This 
may indicate that not only PGRMC1 mediates the intracellular estrogenic effects 
though ERα, but the integrity and phosphorylation of PGRMC1 play also a crucial 
role. 
4.3.2 Estrogen and progetogens affect the transcription level of TFF1 
Trefoil factors 1 (TFF1, formerly pS2), a small cysteine-rich acidic peptide 
consisting of 60 amino acids (Thim. 1989), is regarded as an indicator of the intact 
ER signaling pathway (Henry et al. 1990; Corte et al. 2006). The TFF1 gene 
contains an estrogen response element (ERE) and its expression can be regulated 
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by estrogen. To be specific, estrogen-bound ER is recruited to estrogen response 
elements (ERE) within the TFF1 promoter, resulting in an induction of TFF1 
transcription (Espino et al. 2006). Estrogen stimulation of an estrogen-dependent 
breast cancer cell line induce significant (up to 100 fold) increase of TFF1 mRNA 
as well as an increase of protein level (Masiakowski et al. 1982). Moreover, some 
studies suggested that TFF1 expression might be useful in identifying the subgroup 
of ER-positive breast cancer patients being more responsive to aromatase 
inhibitors (AI) than to Tamoxifen (Zhou et al. 2011).  
Similar result was observed in the present study: E2 stimulation could significantly 
induce the TFF1 transcription in both MCF-7 and T47D PGRMC1-overexpressing 
cell lines, as well as MCF-7 control cells. However, the rise of TFF1 expression 
appeared not to be dose-dependent, and the most efficient concentration for E2 
was 10-9M. Additionally, for the first time, we discovered in the present study that, 
like estrogen, progestegen stimulation can also induce TFF1 transcription. 
Because when the same experiment was performed using NET as the stimulation, 
the effect of increased TFF1 expression was again detected at the concentration of 
10-7M. Moreover, compared with the elevated effect of E2 and NET alone, the 
combination of E2 and NET did not significantly further induce the transcriptional 
level of TFF1. Taken together, these findings would support our assumption that 
PGRMC1 responding to stimulation of estrogen and progestogen and then 
transduced the signal, via a cross-talk with ER, to induce ER related gene 
transcription. Interestingly, although T47D presented a higher sensitivity to 
stimulations in the proliferation experiment compared with MCF-7 cells, the rise of 
TFF1 transcription in T47D cells was not as strong as it in MCF-7 cells.  
In comparison to the classic genomic steroid action involving activation of the 
intracellular transcription factors, which typically occurs over a time scale of hours, 
the novel membrane-associated extranuclear signal transduction pathways is rapid 
and can be initiated within minutes (Revelli et al. 1998; Norman et al. 2004; 
Thomas. 2012). Accordingly, in the present study, we performed a series of 
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experiments to determine the correct time point, when E2 and NET would most 
effectively activate the membrane-associated signaling pathway. However, within 
different time periods of 0.5h, 1h, 2h and 4h, no obvious time-dependent effect was 
found. Due to the narrow range of the time period tested, our data do not clearly 
demonstrate that time is irrelevant in the membrane-associated signaling pathway. 
Therefore, a wider range of time period was required in future studies. 
With regard to other progestins, at the concentration of 10-7M, P4, MPA and CMA 
did not trigger any significant up-regulation of TFF1 transcription, whereas DSP 
and, surprisingly, NOM, which was proved to be neutrally in the proliferation 
experiment, enhanced the expression of TFF1. So far, we do not have explanation 
for this result, but further investigation was required. 
Although PGRMC1 is clearly a component of membrane-associated progesterone 
signaling, its exact role and the mechanisms by which PGRMC1 mediates 
intracellular signaling are unclear, and limited data on signaling pathways through 
PGRMC1 suggest that its action is indirect, and it may act as an adaptor protein for 
a wide variety of proteins, such as multiple P450 proteins, including steroid 
regulatory element-binding protein cleavage activating protein (Scap), insulin-
induced gene and epidermal growth factor receptor (EGFR) (Ahmed et al. 2010). 
And some of these downstream proteins may be keys of the cross-talk with the 
extranuclear ER signaling pathways. For instance, EGFR has been previously 
designated as a mediator of the non-genomic effects of E2. And initial evidence 
has been obtained that cell surface expression of EGFR is associated with 
PGRMC1. A recent publication demonstrated that estrogens and tamoxifen do not 
only exert their effects at the genomic level, but also function at the cell membrane 
activating downstream signaling pathways, since blocking EGFR would reverse the 
inhibitory effect of tamoxifen on breast cancer cells (Raffo et al. 2014).   
4.3.2 Inhibitors block the transcription level of TFF1 
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In the last part of the present study, three inhibitors was applied, fulvestrant, 
AG205 and TBCA. Fulvestrant is widely used as a selective estrogen receptor 
down-regulator for ER positive breast cancer in postmenopausal women, which 
can effectively inhibit estrogen signaling in breast cancer.  And as a PGRMC1 
inhibitor, AG205 alters the spectroscopic properties of the PGRMC1-heme 
complex. And finally, TBCA is a CK2 inhibitor as described above. As expected, 
Inhibition of both ER and PGRMC1 signaling with fulvestrant and AG-205, 
respectively, causes a statistically significant decrease in TFF1 expression in MCF-
7 and T47D breast cancer cells overexpressing PGRMC1, but not in empty vector 
control cells. And a reduction of proliferation rate in breast cancer cells was 
previously observed in our laboratory, when MCF-7 cells were treated with these 
inhibitors (Ruan et al. 2012). Taken together, these results demonstrate not only 
that maintenance of PGRMC1 signaling is required for TFF1 expression, but also 
the involvement of both PGRMC1 and ER during the estrogen/progestogen-
induced TFF1 transcription. 
Although in terms of protein levels, we failed to prove that CK2 was the right kinase 
which led to PGRMC1 phosphorylation, cell proliferation rate in the MTT 
experiment was dramatically reduced after the incubation of TBCA. So far, we did 
not have a better explanation for these conflict results, but the suppression of TFF1 
transcription in MCF-7 and T47D breast cancer cells overexpressing PGRMC1 
caused by TBCA may again indicate a correlation between PGRMC1 
phosphorylation and ER status in the intracellular signaling pathway. Furthermore, 
pharmacological targeting of the cell signaling pathways that regulate PGRMC1 
phosphorylation at certain sites may represent therapeutic targets for modulating 
ER function. 
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5 SUMMARY 
As a treatment, menopausal hormone therapy (MHT) is commonly recommended 
clinically to relieve postmenopausal symptoms, such as hot flushes and sweats, 
and to address long-term biological changes, such as bone loss, that result from 
declining levels of the natural hormones in postmenopausal women. However, 
since the early 1940s, when estrogen was first introduced into clinical practice, the 
concern that MHT may cause breast cancer has existed. Therefore, various 
methods were applied, including case reports, case-control studies and recently 
some large prospective cohort studies, to provide more reliable evidence. 
Consequently, the concepts about MHT and breast cancer have also changed over 
time. According to previous research data from our laboratory, we believe that 
except for the traditional intracellular-located hormone receptors, membrane-
associated signaling pathway which may be activated via progesterone receptor 
membrane component 1 (PGRMC1) is also important in terms of MHT related 
breast cancer risk.  
To further understand the possible breast cancer risk and the mechanisms related, 
MCF-7 and T47D cells were stably transfected with PGRMC1 and mutants, 
respectively. In the present work, the influence of modification of different 
PGRMC1 phosphorylation sites together with various preparations of estrogens 
and progestogens on the proliferation of breast cancer cell lines was determined. 
Moreover, the potential estrogen receptor (ER)-regulated kinase, CK2 (official 
acronym for casein kinase 2 or II), that may participate in the phosphorylation of 
PGRMC1 was detected. Furthermore, the transcription of an ER reporter gene, 
Trefoil factors 1 (TFF1, formerly pS2), in these two breast cancer cell models, was 
evaluated, to prove the involvement of a cross-talk between PGRMC1 and 
estrogen receptor (ER) in estrogen/progestogen-regulated breast cancers. 
Results from the present study clearly demonstrated that different progestogens as 
well as estrogens can induce, in varying degrees, the proliferation of PGRMC1 
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over-expressing breast cancer cells. And breast cancer cells containing various 
PGRMC1 mutans responded differently to stimulations, due to certain PGRMC1 
phosphorylation sites. Moreover, both ER and CK2 inhibitor can significantly 
reverse the proliferative effect of progestogens and estrogens on PGRMC1 over-
expressing breast cancer cells, which may indicate the vital role of ER status and 
CK2 in the membrane-associated PGRMC1 signaling pathway. However, western 
blot did not provide any strong evidence that CK2 was mandatory in PGRMC1 
phosphorylation, although PGRMC1 was indeed phosphorylated after the 
stimulation of progestogens as well as estrogens. Therefore, an improvement of 
the current methods of proving the kinase or a thorough search of the right kinase 
which may cause the phosphorylation of PGRMC1 was required in future study. 
Furthermore, the data has also exhibited that the transcription of the estrogen-
induced ER reporter gene, TFF1, in PGRMC1-overexpressing breast cancer cells, 
was significantly amplified by the stimulation of various progestogens and 
estrogens, which may again implicate the importance of ER in the membrane-
associated PGRMC1 signaling pathway. Finally, a significant suppression of TFF1 
transcription in breast cancer cells overexpressing PGRMC1, caused by three 
different inhibitors, was observed, which revealed the correlation between 
PGRMC1, CK2 and ER status. Thus blocking of ER activity by endocrine therapies 
seems also to be an effective mechanism to reduce breast cancer risk in patients 
overexpressing PGRMC1 whereby additional blocking by PGRMC1 and CK2-
inhibitors may add some benefit in the development of resistance to endocrine 
therapy.  
All the estrogens and progestogens applied in this study are also commonly used 
as MHT in postmenopausal women. Our results suggest that in terms of breast 
cancer risk in women overexpressing PGRMC1 kind and dosage of the estrogen 
and progestogen used should be considered.  
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6 ZUSAMMENFASSUNG 
Menopause Hormontherapie (MHT) ist eine Behandlung, die häufig 
postmenopausalen Frauen empfohlen wird, um postmenopausale Symptome wie 
Hitzewallungen und Schweißausbrüche zu lindern, und um langfristige biologische 
Veränderungen wie Knochenschwund zu behandeln. Doch seit den frühen 1940er 
Jahren, als Östrogene erstmalig in der klinischen Praxis eingeführt wurden, 
existierte die Sorge, dass MHT Brustkrebs verursachen konnte. Daher wurden 
verschiedene Methoden angewandt, einschließlich Fallberichten, 
Fallkontrollstudien und einigen großen prospektiven Kohortenstudien, um den 
Zusammenhang zwischen MHT und einem erhöhten Brustkrebsrisiko zu 
untersuchen. Nach den bisherigen Forschungsergebnissen aus unserem Labor, 
vermuten wir, dass außer den traditionellen intrazellulären Hormonrezeptoren auch 
membranassoziierte Signalwege, die über Progesteronrezeptor-
Membrankomponente 1 (PGRMC1) aktiviert werden können, in Bezug auf das mit 
MHT verbundene mögliche Brustkrebsrisiko wichtig sein können. Um das mögliche 
Brustkrebsrisiko und die zusammenhängenden Mechanismen weiter zu verstehen, 
wurden MCF-7 und T47D Zellen jeweils mit PGRMC1 und Mutanten stabil 
transfiziert. In der vorliegenden Arbeit wurde die Wirkung verschiedener Östrogene 
und Gestagene auf die Proliferation dieser PGRMC1-Varianten untersucht. Als 
Vertreter für mögliche Signalwege wurde die Caseinkinase 2 (CK2) herangezogen, 
die vermutlich an der Phosphorylierung von PGRMC1 beteiligt ist. Weiterhin wurde 
die Transkription eines ER-Reportergens, Kleeblatt-Factor 1 (TFF1, ehemals PS2), 
gemessen, um eine Interaktion zwischen PGRMC1 und Östrogenrezeptor (ER) am 
Östrogen/Gestagen-vermittelten Brustkrebs  zu untersuchen.  
Die Ergebnisse der vorliegenden Studie zeigen deutlich, dass verschiedene 
Gestagene sowie Östrogene die Proliferation beider PGRMC1-überexprimierenden 
Mammakarzinomzell-Linien steigern kann. Aufgrund bestimmter PGRMC1 
Phosphorylierungsstellen reagierten die verschiedenen PGRMC1 Mutanten 
unterschiedlich auf die Steroidhormone. Wir konnten beobachten, dass sowohl ER- 
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als auch CK2-Inhibitoren die proliferativen Effekte von Östrogenen und 
Gestagenen signifikant eliminierten, was darauf hindeutet, dass der ER-Status und 
CK2 eine Schlüsselrolle in den membranassoziierten PGRMC1 Signalwegen 
spielen könnte. Obgleich PGRMC1 durch Stimulationen von Östrogenen und 
Gestagenen phosphoryliert wird, können die im Western Blot erhaltenen Daten 
nicht zwingend darauf hinweisen, dass CK2 bei der PGRMC1 Phosphorylierung 
notwendig ist. Darum wurde entweder eine Verbesserung der derzeitigen 
Methoden oder eine gründliche Suche nach der richtigen Kinase, die die 
Phosphorylierung von PGRMC1 verursachen kann,  in weiterer Studie erforderlich. 
Außerdem können wir zeigen, dass sich die Transkription des Östrogen-
induzierten ER Reportergens, TFF1, von PGRMC1-überexprimierenden 
Mammakarzinomzell-Linien durch Stimulation mit Östrogenen und Gestagenen 
signifikant verstärkt wurde, was die Bedeutung von ER an membranassoziierten 
PGRMC1 Signalwegen unterstreicht. Wir konnten hierbei beobachten, dass die 
Zunahme der TFF1-Expression von PGRMC1-überexprimierenden Mamma-
karzinomzell-Linien durch drei Inhibitoren (ER-, PGRMC1 und CK2-Inhibitor) 
signifikant reduziert werden konnte, was auf eine Korrelation zwischen PGRMC1, 
CK2 und ER-Status hindeutet. Somit ist eine ER-Blockade zur Reduzierung  für die 
beobachtete proliferative Effekt von Östrogenen und Gestagenen erfordlich wäre, 
würde die Stilllegung von ER die PGRMC1- vermittelte Proliferation auf jeden Fall 
verringern, was eine interessante Richtung für unsere zukünftige Studien wäre. 
Alle Östrogene und Gestagene, die in dieser Studie untersucht wurden, sind 
üblicherweise als MHT bei postmenopausalen Frauen in Anwendung. Unsere 
Untersuchungen deuten daraufhin, dass das Brustkrebsrisiko bei Frauen mit 
erhöhter PGRMC1-Expression durch Art und Dosierung der verwendeten 
Östrogene und Gestagene beeinflusst werden könnte. 
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